# Reactive oxygen species prevent lysosome coalescence during PIKfyve inhibition

- 3
- 4 Golam T. Saffi<sup>1,2,3</sup>, Evan Tang<sup>2</sup>, Subothan Inpanathan<sup>1,2</sup>, Sami Mammad<sup>1</sup>, Aaron Fountain<sup>1,2</sup>
- 5 Leonardo Salmena<sup>3,4</sup>, and Roberto J. Botelho<sup>1,2,\*</sup>
- <sup>6</sup> <sup>1</sup>Molecular Science Graduate Program and <sup>2</sup>Department of Chemistry and Biology, Ryerson
- 7 University, Toronto, Ontario, M5B 2K3 Canada
- <sup>8</sup> <sup>3</sup>Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario M5S
- 9 1A8, Canada
- <sup>4</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7,
- 11 Canada
- 12
- 13 \*To whom correspondence should be sent to: rbotelho@ryerson.ca
- 14
- 15 **Running title:** Reactive oxygen species prevent lysosome enlargement

16

17 Keywords: Lysosomes, reactive oxygen species, membrane trafficking, organelles, fusion,
18 fission, cytoskeleton

19

20 Abbreviations: CDNB: 1-chloro-2,4,-dinitrobenzene; FBS: fetal bovine serum; HPF: 21 hydroxylphenyl fluorescein; LAMP1: lysosomal membrane protein-1; LLMeO: L-leucyl-L-22 leucine methyl ester; MCB: monochlorobimane; MCOLN1: Mucolipin-1; NAC: N-acetyl-L-

23	cysteine; PFA: paraformaldehyde; PtdInsP: phosphoinositide; PtdIns(3,5)P <sub>2</sub> : phosphatidylinositol-
24	3,5-bisphosphate; RILP: Rab-Interacting Lysosomal Protein; ROS: reactive oxygen species
25	
26	Acknowledgement: ARPE-1 (RPE) cells stably expressing clathrin heavy chain-eGFP were a
27	kind gift from Dr. Costin Antonescu. We would also like to thank Mr. Janusan Baskararajah for
28	technical assistance.
29	Funding: This work was funded by grants awarded to RJB from the Natural Sciences and
30	Engineering Council of Canada (Grant numbers 372687-2010, 441595-2013, RGPIN-2020-
31	04343) the Canada Research Chairs Program, Canada Foundation for Innovation (32957) an Early
32	Researcher Award from the Government of Ontario (ER13-09-042), and contributions from
33	Ryerson University. The funders had no role in the study design, data collection and analysis,
34	decision to publish, or preparation of the manuscript.

### 35 Abstract

36 Lysosomes are terminal, degradative organelles of the endosomal pathway that undergo repeated 37 fusion-fission cycles with themselves, endosomes, phagosomes, and autophagosomes. Lysosome 38 number and size depends on balanced fusion and fission rates. Thus, conditions that favour fusion 39 over fission can reduce lysosome numbers while enlarging their size. Conversely, favouring fission 40 over fusion may cause lysosome fragmentation and increase their numbers. PIKfyve is a 41 phosphoinositide kinase that generates phosphatidylinositol-3,5-bisphosphate to modulate 42 lysosomal functions. PIKfyve inhibition causes an increase in lysosome size and reduction in 43 lysosome number, consistent with lysosome coalescence. This is thought to proceed through 44 reduced lysosome reformation and/or fission after fusion with endosomes or other lysosomes. 45 Previously, we observed that photo-damage during live-cell imaging prevented lysosome

46 coalescence during PIK fyve inhibition. Thus, we postulated that lysosome fusion and/or fission 47 dynamics are affected by reactive oxygen species (ROS). Here, we show that ROS generated by 48 various independent mechanisms all impaired lysosome coalescence during PIKfyve inhibition 49 and accelerated lysosome fragmentation during re-activation. However, depending on the ROS 50 species or mode of production, lysosome dynamics were affected distinctly. H<sub>2</sub>O<sub>2</sub> impaired 51 lysosome motility and reduced lysosome fusion with phagosomes, suggesting that H<sub>2</sub>O<sub>2</sub> reduces 52 lysosome fusogenecity. In comparison, inhibitors of oxidative phosphorylation, glutathione, and 53 thioredoxin that produce superoxide, did not impair lysosome motility but instead promoted 54 clearance of actin puncta on lysosomes formed during PIKfyve inhibition. Additionally, actin 55 depolymerizing agents prevented lysosome coalescence during PIKfyve inhibition. Thus, we 56 discovered that ROS can generally prevent lysosome coalescence during PIKfyve inhibition using 57 distinct mechanisms depending on the type of ROS.

58

### 59 Introduction

60 Lysosomes are typically defined as terminal organelles with an acidic and degradative lumen that 61 digest macromolecules received through endocytosis, phagocytosis and autophagy [1–3]. In 62 reality, lysosomes are part of an endomembrane spectrum formed through heterotypic and 63 homotypic fusion between late endosomes that enclose cargo for degradation, terminal lysosomes, 64 which are non-acidic, hydrolase-dormant storage organelles, and endolysosomes, hybrids formed 65 when late endosomes and terminal lysosomes fuse together [4–7]; we use the term lysosome to 66 refer to this spectrum. Importantly, fusion and content exchange along the lysosomal spectrum 67 proceeds through two major routes. First, lysosomes can fuse with a target organelle resulting in 68 complete merger of the two compartments. Alternatively, lysosomes can exchange content with

another target organelle through "kiss-and-run"; in this process, a transient fusion between two
organelles generates an aqueous pore to exchange content and is followed by fission to prevent
amalgamation of the two compartments [6,8–10].

72 Delivery of cargo to lysosomes is an incessant process that depends on cargo sorting, 73 membrane targeting, and the fusion machinery, which are governed by, among others, the 74 lysosomal GTPases, Rab7 and Arl8b [11,12]. These GTPases modulate the movement of 75 lysosomes along microtubule tracks through their effectors; Rab7 uses Rab-Interacting Lysosomal 76 Protein (RILP) and FYVE and Coiled-Coil Domain Autophagy Adaptor-1 (FYCO1) to engage 77 dynein and kinesins, thus moving lysosomes towards the cell centre and periphery, respectively 78 [13,14]. In comparison, Arl8b uses Pleckstrin-Homology and RUN domain containing M2 79 (PLEKHM2; or SKIP) protein to engage kinesin to promote lysosome positioning to the cell 80 periphery [15]. When lysosomes contact other lysosomes/late endosomes, this engages tether 81 complexes like Homotypic Fusion Protein Sorting (HOPS) complex, also modulated by Rab7 and 82 Arl8b, and eventually undergo fusion [12,16,17]. Lysosome fusion and fission dynamics is also 83 modulated by intralysosomal Ca<sup>2+</sup> release via Mucolipin-1 (MCOLN1) and P2X4 channels 84 [18,19].

Despite the incessant delivery of content to lysosomes through fusion, cells maintain lysosome number and size, suggesting that exit of cargo from lysosomes by fission is also relentless. Yet, much less is known about lysosome fission, which may proceed through vesiculation, tubulation, and splitting [10]. Lysosome fission mechanisms may include classical coat and fission machinery such as clathrin and dynamin and actin complexes [10,20–24]. Coordination of these fission machines is poorly understood but likely involves MCOLN1-Ca<sup>2+</sup> release [19,25,26]. Additionally, phosphoinositides (PtdInsPs) play a key role in lysosome fission

92 dynamics including modulation of vesiculation versus tubulation [10]. Amongst these, lysosome 93 fission-fusion cycles are coordinated by the Phosphoinositide Kinase, FYVE-type Zinc Finger 94 Containing (PIKfyve) lipid kinase that synthesizes phosphatidylinositol-3,5-bisphosphate 95 indirectly,  $[PtdIns(3,5)P_2]$ and directly or phosphatidylinositol-5-phosphate [27,28]. Pharmacological or genetic disruption of PIKfyve and partner proteins like Vac14 and the Fig4 96 97 phosphatase cause enlarged lysosomes, partly by impairing fission and reformation of terminal 98 lysosomes [4,27,29–31]. The result is lysosome coalescence, enlarging lysosomes while reducing 99 their numbers [4,30]. It remains unclear how PIKfyve controls lysosome fission but may involve 100 control of actin-assembly on lysosomes and fission proteins [19,21,26,32].

101 During our studies with acute PIKfyve inhibition, we observed that imaging by spinning 102 disc confocal microscopy at high frequency inhibited lysosome enlargement caused by PIKfyve 103 inhibition [30]. We speculated that this resulted from photo-generated reactive oxygen species 104 (ROS), which can include superoxide anions  $(O_2)$ , hydrogen peroxide  $(H_2O_2)$ , and hydroxyl 105 radicals (OH<sup>•</sup>) [33–35]. ROS species are also formed as part of normal aerobic metabolism and 106 can actually be produced as signaling intermediates to modulate cell proliferation and the 107 inflammatory response [36,37]. Yet, overt ROS production is detrimental, damaging proteins, 108 lipids, and DNA. Thus, cells have evolved multiple systems to quench ROS levels such as  $O_2^{-1}$ 109 dismutase, catalase, glutathione, and thioredoxin [37,38].

In this study, we sought to understand if other modes of ROS generation could abate lysosome coalescence during PIKfyve inhibition and to better define the mechanisms of action. Strikingly, we found that different sources of ROS reduced lysosome coalescence during PIKfyve inhibition and accelerated lysosome fragmentation upon PIKfyve reactivation. Interestingly, these distinct ROS hindered lysosome coalescence differently. H<sub>2</sub>O<sub>2</sub> prevented lysosome coalescence by impairing lysosome motility and blunting lysosome fusogenecity. In comparison, oxidative decoupling of the mitochondria with rotenone and inhibitors of glutathione and thioredoxin counteracted lysosome coalescence by releasing actin clusters that accumulated on lysosomes during PIKfyve impairment.

119

## 120 **Results**

# Stimulation of ROS suppresses lysosome enlargement during acute PIKfyve inhibition

We previously observed that extended laser excitation by spinning disc confocal fluorescence 123 124 microscopy arrested lysosome enlargement during acute PIKfyve suppression [30]. We speculated 125 that this arrest may be due to ROS production caused by light energy [39]. This led us to 126 hypothesize that other mechanisms of ROS generation could impair lysosome enlargement during 127 acute inhibition of PIKfyve. To test this, we exposed cells to a variety of ROS inducers:  $H_2O_2$ , 128 rotenone, which decouples the mitochondrial electron chain, monochlorobimane (MCB), a 129 glutathione S-transferase inhibitor, or to the thioredoxin inhibitor, 1-chloro-2,4,-dinitrobenzene 130 (CDNB) [35,40–42]. We first demonstrated that these manipulations enhanced ROS levels by 131 using CellROX Green, a redox sensitive dye whose fluorescence is proportional to ROS levels 132 (Figs 1A-B). Additionally, ROS cause MCB to form fluorescent MCB-glutathione adducts; we 133 observed 7x more MCB-glutathione adducts relative to vehicle (Fig 1C-1D). To better define the 134 type(s) of ROS generated by these treatments, we used fluorescent detectors for  $O_2^{-}$  (ROS-ID), 135 mitochondrial O<sub>2</sub><sup>-</sup> (MitoSox), OH<sup>-</sup>/peroxynitrite (HPF), and singlet O<sub>2</sub><sup>-</sup> (si-DMA). We found that 136 H<sub>2</sub>O<sub>2</sub> was the most promiscuous agent generating all species except detectable levels of singlet O<sub>2</sub>.

(Fig 1E-H). In turn, rotenone generated mitochondrial O<sub>2</sub><sup>-</sup> and singlet O<sub>2</sub><sup>-</sup> as detected by MitoSox

and si-DMA, respectively (Fig 1E-H), while CDNB favoured production of singlet O<sub>2</sub><sup>-</sup> (Fig 1EH). MCB did not elicit detectable changes in these probes, though ROS were detected when using
CellRox and GSH-MCB (Fig 1-D).

137

141 Remarkably, we then observed that all ROS inducers arrested lysosome enlargement in 142 cells treated with apilimod, a potent and selective PIKfyve blocker (Fig 2). More specifically, 143 RAW cells treated with apilimod alone suffered an increase in the size of individual lysosomes 144 (Fig 2B) and a decrease in lysosome number (Fig 2C), indicating that lysosomes coalesced. As we 145 documented before, the total cellular volume of the lysosome population was unchanged between 146 resting and apilimod-treated cells (Fig 2D). In comparison, co-exposure of cells with apilimod to 147 either H<sub>2</sub>O<sub>2</sub>, rotenone, MCB or CDNB prevented lysosome enlargement and reduction in lysosome 148 number (Fig 2A-D). Moreover, we used auranofin as a complementary thioredoxin inhibitor to 149 CDNB and observed that it too prevented apilimod-induced lysosome coalescence (Fig 2A-D). To 150 test whether lower  $H_2O_2$  levels (100  $\mu$ M) could also block lysosome coalescence, we used lower 151 apilimod concentrations (1 or 5 nM). We still observed lysosome coalescence at these lower 152 concentrations of apilimod and this was prevented in cells that were co-exposed to  $100 \,\mu\text{M}$  H<sub>2</sub>O<sub>2</sub> 153 (S1 Fig). No significant changes to lysosome number, size of individual lysosomes and total 154 lysosome volume were observed when ROS agonists were used alone (Fig 2A-D). The fact that 155 ROS alone did not appear to further reduce lysosome size and increase lysosome number may 156 reflect some physical restriction to the smallest lysosome size; for example, osmotic pressure may 157 prevent a further reduction in the size of basal lysosomes.

158 To provide evidence that ROS were the active agents that blocked lysosome coalescence 159 during apilimod-treatment, we employed N-acetyl-L-cysteine (NAC) as an anti-oxidant during

rotenone co-administration [43]. Indeed, cells co-exposed with apilimod, rotenone and NAC
displayed larger lysosomes than cells co-treated with apilimod and rotenone (Fig 3), indicating
that ROS are the active agents arresting lysosome enlargement during PtdIns(3,5)P<sub>2</sub> depletion.

163 To ensure that these observations were not specific to murine RAW macrophages, we 164 assessed apilimod-induced lysosome coalescence in human-derived RPE and HeLa cells co-165 exposed to H<sub>2</sub>O<sub>2</sub> or CDNB. As with RAW cells, while apilimod-alone induced lysosome 166 coalescence in HeLa and RPE cells, counterpart cells co-administered apilimod and  $H_2O_2$  or 167 CDNB resisted lysosome enlargement and reduction in lysosome number (S2 Fig). As before, no 168 changes were observed under any treatment to the total lysosomal volume within these cell types 169 (S2D, S2H Figs). Overall, our observations suggest that generation of ROS via distinct 170 mechanisms can impair lysosome coalescence caused by PIKfyve inhibition in several cell types.

### 171 **ROS accelerate lysosome fragmentation during PIKfyve reactivation**

172 Removal of apilimod elicited reversal of lysosome coalescence, re-establishing lysosome size and 173 number after >3 h post drug removal [30]. To test if ROS exposure could accelerate this reversal 174 in lysosome coalescence, we treated RAW cells with apilimod for 1 h and then incubated cells 175 with fresh, drug-free medium to reactivate PIKfyve with or without H<sub>2</sub>O<sub>2</sub>, rotenone, CDNB, or 176 MCB during this wash duration. As before, apilimod increased lysosome size and decreased 177 lysosome number, while chasing cells for 2 h after drug removal reversed this phenotype partly; 178 longer incubation ultimately reverses lysosome enlargement completely [30]. Exposure to any of 179 the ROS agents during the apilimod-free chase accelerated the rate of lysosome fragmentation, 180 rapidly increasing lysosome number and reducing the size of individual lysosomes (Fig 4A-D).

181 Overall, ROS prevented and reversed lysosome coalescence induced by PIKfyve
182 inhibition. We next examined levels of PtdIns(3,5)P<sub>2</sub>, lysosome membrane damage, lysosome

motility, fusion and fission events in order to better understand the mechanisms that enable ROS
to prevent lysosome coalescence in the absence of PIKfyve activity.

# 185 ROS stimulation arrests apilimod induced lysosome enlargement 186 without neutralizing apilimod or stimulating PtdIns(3,5)P<sub>2</sub> synthesis

To understand the effect of ROS on apilimod-mediated lysosome enlargement, we first considered 187 188 the trivial possibility that higher ROS load within cells may degrade the structural integrity of 189 apilimod, relieving the acute PIK fyve suppression, and thus preventing lysosome coalescence. To 190 test this, we co-incubated apilimod with H<sub>2</sub>O<sub>2</sub> in complete medium *in vitro* for 40 min. Following 191 this incubation, we added catalase to decompose  $H_2O_2$  and then transferred the reaction mixture 192 onto RAW macrophages to observe if apilimod was still able to induce lysosome enlargement. We 193 found that apilimod pre-exposed to  $H_2O_2$  was still able to increase lysosome size and decrease 194 lysosome number similarly to an aliquot of naïve apilimod (Fig 5A-D), suggesting that H<sub>2</sub>O<sub>2</sub> did 195 not degrade apilimod. Moreover, while  $H_2O_2$  arrested apilimod-mediated lysosome enlargement, 196 the co-addition of catalase to apilimod and H<sub>2</sub>O<sub>2</sub> permitted lysosome enlargement, further 197 suggesting that  $H_2O_2$  is a direct suppressor of lysosome coalescence in PIKfyve-inhibited cells 198 (Fig 5A-D). Therefore, we provide additional evidence that ROS rescue lysosome coalescence 199 during acute PIKfyve inhibition.

We next examined if ROS rescue lysosome coalescence during PIKfyve inhibition by increasing the levels of PtdIns(3,5)P<sub>2</sub> in cells. In part, this may occur because ROS species reversibly oxidize catalytic cysteine residues on protein and lipid phosphatases, abating their activity [37,44,45]. Therefore, augmented ROS levels may inhibit the Fig4 lipid phosphatase, counteracting PIKfyve inhibition with apilimod and boosting PtdIns(3,5)P<sub>2</sub> levels [31]. This putative PtdIns(3,5)P<sub>2</sub> elevation may then be sufficient to prevent lysosome coalescence in cells

206 exposed to apilimod and ROS. To test this hypothesis, we measured PtdInsP levels in cells treated 207 with H<sub>2</sub>O<sub>2</sub> or rotenone with and without apilimod by labelling cells with <sup>3</sup>H-myo-inositol and using 208 HPLC-coupled flow scintillation [46]. However, we observed a similar drop of about 80% in 209 Ptdns(3,5)P<sub>2</sub> in cells treated with apilimod with or without ROS agents (Fig 5E, F), suggesting that 210 ROS stimulation does not significantly elevate  $PtdIns(3,5)P_2$  levels. In addition, inhibition of 211 PIKfyve typically causes an increase in PtdIns(3)P levels (Fig 5E, F). While rotenone had no effect 212 on this increase, H<sub>2</sub>O<sub>2</sub> appeared to prevent this spike in PtdIns(3)P levels during apilimod treatment 213 (Fig 5E). The significance of this change is not clear to us but given that rotenone still increased 214 PtdIns(3)P and prevented lysosome coalescence, it is not likely to explain our observations. 215 Overall, ROS prevents lysosome coalescence during PIKfyve inhibition via a mechanism that is 216 independent of  $PtdIns(3,5)P_2$  levels.

### 217 **ROS alter the microtubule system**

218 Since PtdIns(3,5)P2 levels do not illuminate how ROS prevent lysosome coalescence during 219 PIKfyve inhibition, we assessed other processes that affect lysosome dynamics. First, we examined 220 whether ROS altered the microtubule system given its role in facilitating homotypic and 221 heterotypic lysosome fusion. In fact, we previously showed that disruption of the microtubule 222 system and microtubule motor activity blocked lysosome coalescence during PIKfyve inhibition 223 [30]. We inspected the microtubule system in RAW macrophages (Fig 6A-D) and RPE cells (Fig 224 6E-H) exposed to the ROS agents by immunofluorescence staining against  $\alpha$ -tubulin. We observed 225 that the ROS agonists altered the microtubule system, but in distinct ways. Relative to untreated 226 RAW macrophages or RPE cells, qualitative analysis of immunofluorescence images suggest that 227 H<sub>2</sub>O<sub>2</sub> makes microtubules more stable and extended, whereas increasing concentrations of 228 rotenone, CDNB and MCB seemed to depolymerize microtubules, resulting in shorter

229 microtubules and diffused staining (Fig. 6). As a proxy to quantify changes to the microtubule 230 morphology, we employed and validated the use of ImageJ "skeleton" plugin to extract different 231 parameters of microtubule structure; these included filament junctions, branching, branch length, 232 and patch area (S3 Fig). It is important to state that these are proxies rather than absolute 233 descriptors of microtubule morphology. Using these measures, we were able to quantitatively 234 show that all four ROS types altered the microtubule system with distinct effects. Briefly, H<sub>2</sub>O<sub>2</sub> 235 increased the number of microtubule junctions per cell and branch length in both RAW and RPE 236 cells (Fig 6B, D, F and H). In comparison, rotenone, CDNB and MCB decreased the number of 237 microtubule junctions and branches per cell significantly in RAW cells and increased the patch 238 area in RPE cells (Fig. 6B, C, I). These observations indicate that type of ROS and/or the site of 239 ROS synthesis differentially affects microtubules, and potentially lysosome dynamics.

### 240 **Disparate ROS effects on lysosome motility**

To dissect these observations further, we considered that microtubule disruption would impair 241 242 lysosome motility and/or lysosome fusion. To test this model, we quantified lysosome motility and 243 the ability of lysosomes to fuse with phagosomes. First, we conducted live-cell imaging over 3 244 and 6 min for RAW macrophages (Fig. 7A-C, Movies 1-6) and RPE cells (Fig. 7D-F, Movies 7-245 13), respectively, treated with vehicle or ROS agents. Using these videos, we then extracted 246 lysosome speed, track length, and vectorial displacement as indicators of lysosome motility. To 247 our surprise, H<sub>2</sub>O<sub>2</sub> was the only ROS agent that reduced lysosome speed, track length and vectorial 248 displacement in RAW and in RPE cells, with the strongest effect on the latter cell type (Fig. 7). To 249 understand whether microtubule stability was sufficient to impair lysosome coalescence or affect 250 lysosome motility, we performed a control experiment by treating RAW cells with paclitaxel, a 251 microtubule stabilizing agent [47]. However, paclitaxel did not impair lysosome coalescence

caused by apilimod and may actually enhance lysosome motility indicators (S4 Fig, Movies 14-16), suggesting that H<sub>2</sub>O<sub>2</sub> blocks apilimod-mediated lysosome enlargement via a distinct mechanism, perhaps by displacing motors from lysosomes or impairing motor activity. If so, this does not seem to occur by reducing the levels of GTP-Rab7 or Arl8b GTPase loaded onto lysosomes as measured by imaging and membrane fractionation (S5 Fig).

257 Given the impaired lysosome motility caused by  $H_2O_2$ , we next sought to determine if  $H_2O_2$ 258 also hindered lysosome fusogenecity by examining phagosome-lysosome fusion as a model. RAW 259 cells were treated with  $H_2O_2$  or vehicle for 1 h, followed by phagocytosis of bacteria for 20 min 260 and a chase period of 40 min to permit phagosome maturation. The degree of phagosome-lysosome 261 fusion was assessed by quantifying the amount of LAMP-1 fluorescent signal present on bacteria-262 containing phagosomes. We observed that H<sub>2</sub>O<sub>2</sub>-treated RAW cells had less LAMP-1 fluorescence 263 signal localized to bacteria-containing phagosomes compared to vehicle-treated RAW 264 macrophages (Fig 8). This suggests that  $H_2O_2$  impaired the ability of lysosomes to fuse with target 265 organelles, consistent with reduced lysosome motility. Overall, we propose that  $H_2O_2$  prevents 266 lysosome coalescence during PIKfyve inhibition by impairing lysosome motility and the 267 probability of fusion with other organelles, including phagosomes or other lysosomes.

In comparison to H<sub>2</sub>O<sub>2</sub>, rotenone, MCB and CDNB did not impair measures of lysosome motility in RAW macrophages or RPE cells (Fig 7A-C) at concentrations sufficient to block apilimod-induced lysosome coalescence. Interestingly, nocadozole strongly impaired all measures in RPE cells but had mild effects on RAW cells (Fig 7). This is likely because RAW macrophages depolymerized for microtubules appeared to become rounder and taller, causing a wobbling motion that moved lysosomes in bulk (see Supplemental Movies 1-6). In comparison, RPE cells were flatter and more resistant to this oscillating effect (see Supplemental Movies 7-13). Given that nocodazole in RPE cells hindered lysosome motility, but CDNB, MCB and rotenone had no effect on lysosome motility measures in RPE cells, this suggests that rotenone, CDNB and MCB only partially disrupt the microtubule system. Thus, the extent of microtubule depolymerization caused by rotenone, CDNB and MCB is not sufficient to explain how these agents prevent lysosome enlargement during apilimod treatment.

### 280 **ROS effects on lysosome membrane damage and Ca<sup>2+</sup> release**

281 Given the above, we next assessed if and how ROS affected other lysosome properties. One 282 possibility is that ROS damage the membrane of lysosomes altering their dynamics. To test this, 283 we transfected RAW macrophages with galectin-3-GFP, which labels damaged lysosomes with 284 exposed luminal glycoproteins to the cytosol [48,49]. Strikingly, under the conditions used, H<sub>2</sub>O<sub>2</sub> 285 or rotenone did not induce a significantly higher number of galectin-3-GFP punctate relative to 286 vehicle-treated cells. As a positive control, we observed a much higher number of galectin-3-GFP 287 puncta in cells exposed to the lysosome damaging agent, LLMeO (Fig 9). Thus, we suspect that 288 membrane damage cannot account for the broad ROS-mediated prevention of lysosome 289 enlargement during PIKfyve inhibition.

290 We next considered if ROS could trigger release of lysosomal Ca<sup>2+</sup>, which in turn could 291 alter lysosome dynamics [25,50]. In fact, ROS have been connected to release of lysosomal Ca<sup>2+</sup> 292 via MCOLN1 [51]. To examine if lysosomal  $Ca^{2+}$  is released by ROS agents, we quantified the lysosome-to-cytosol fluorescence ratio of Fluo4-AM, a Ca<sup>2+</sup> sensor [52,53], in rotenone and H<sub>2</sub>O<sub>2</sub>-293 294 treated cells. Whereas rotenone had no apparent effect in this ratio, we observed an increase in cytosolic Ca<sup>2+</sup> levels relative to lysosome in H<sub>2</sub>O<sub>2</sub>-treated cells (Fig. 10A, B). However, pre-295 296 treating cells with BAPTA-AM did not affect basal lysosome number and volume, or block 297 apilimod-induced lysosome coalescence, nor did it alter H<sub>2</sub>O<sub>2</sub> or rotenone prevention of lysosome

coalescence (Fig. 10C-F). Overall, the data suggest that the effects by ROS are not likely mediated
by Ca<sup>2+</sup> or lysosome damage.

# Clathrin and dynamin are not required for ROS-induced lysosome fragmentation

302 Lysosomes and related organelles such as autolysosomes can assemble fission machinery, 303 including the canonical fission components, clathrin and dynamin [10,23,24,54]. We sought to 304 determine if ROS species like H<sub>2</sub>O<sub>2</sub> stimulate clathrin and dynamin-2 to boost fission and prevent 305 lysosome coalescence during PIKfyve inhibition. First, we observed no changes in the levels of 306 lysosome-associated clathrin-eGFP in vehicle or apilimod-treated RPE cells. In comparison, clathrin-eGFP was recruited at higher levels to lysosomes labelled with Alexa<sup>546</sup>-conjugated 307 308 dextran after H<sub>2</sub>O<sub>2</sub> treatment in both the presence or absence of apilimod (S6A-B Fig). To 309 complement our observations, we treated RAW 264.7 cells with vehicle or H<sub>2</sub>O<sub>2</sub>, followed by 310 sucrose gradient ultracentrifugation to fractionate organelles and probed for clathrin and dynamin 311 by Western blotting. We saw a consistent increase in the level of clathrin and dynamin-2 to 312 LAMP1-positive lysosome fractions in cells treated with  $H_2O_2$  relative to resting cells (S6C-E 313 Fig). To test whether this enhanced recruitment of clathrin and dynamin aided in lysosome 314 fragmentation during PIK fyve reactivation in the presence of  $H_2O_2$ , we inhibited clathrin and 315 dynamin with ikarugamycin and dyngo-4a, respectively [55,56]. Nevertheless, there was no 316 significant difference in the H<sub>2</sub>O<sub>2</sub>-mediated rescue of lysosome coalescence during PIKfyve 317 reactivation when clathrin or dynamin were arrested (Fig 11, S7 Fig). Similarly, there was no 318 difference in lysosome fragmentation during rotenone exposure when cells were incubated with 319 dyngo-4a (S7 Fig). Overall, while at least H<sub>2</sub>O<sub>2</sub> seems to recruit clathrin and dynamin to lysosomes

(and perhaps other membranes), our data do not support a role for clathrin and dynamin inpreventing lysosome coalescence during PIKfyve inhibition under the used conditions.

### **ROS prevents lysosome coalescence by actin depolymerization**

323 There is growing evidence that F-actin-based structures may regulate endosomal and lysosomal 324 fission, either through the action of acto-myosin constriction or the assembly of fission machinery 325 that remains to be fully defined [10,21,57]. In fact, work by Hong et al. suggests that PIKfyve 326 inhibition causes branched actin accumulation on endosomes; based on their markers used to 327 identify endosomes, lysosomes were likely included in their analysis [21]. We set to understand 328 if at least some ROS can prevent lysosome coalescence during PIKfyve inhibition by eliminating 329 these F-actin assemblies on lysosomes. Indeed, PtdIns(3,5)P<sub>2</sub> depletion increased the number of 330 F-actin puncta associated with lysosomes detectable by fluorescent-phalloidin staining (Fig 12A, 331 B), as previously reported [58,59]. Interestingly, co-administration of rotenone or CDNB with 332 apilimod reduced F-actin puncta associated with lysosomes (Fig 12A, B). These observations 333 indicate that ROS generated by rotenone and CDNB help prevent or reverse lysosome coalescence 334 during PIKfyve inhibition by boosting actin turnover on lysosomes.

335 To further test whether actin depolymerization helps prevent lysosome coalescence during 336 PIKfyve inhibition and accelerate lysosome fragmentation during PIKfyve inhibition, we 337 compared lysosome volumetrics in cells treated with the actin depolymerizing agents, cytochalasin 338 B or latrunculin A. We found that both cytochalasin B and latrunculin A treatments hindered 339 lysosome coalescence during apilimod treatment, as well as accelerated lysosome fragmentation 340 after apilimod removal and PIKfyve reactivation (Fig 12C-F). Collectively, our observations 341 suggest that at least certain types of ROS prevent lysosome coalescence during acute PIKfyve 342 inhibition by alleviating F-actin amassed on lysosomes, likely facilitating fission.

343

## 344 **Discussion**

345 Low  $PtdIns(3,5)P_2$  levels causes multiple defects including impaired autophagic flux, nutrient 346 recycling, and phagosome resolution [10,27]. These defects are likely derived from the inability 347 of lysosomes to reform or separate after fusion with other lysosomes, late endosomes, phagosomes, 348 and autolysosomes [4,10,30,60,61]. As a corollary, lysosomes coalesce to become larger but fewer 349 [4,30]. Thus, identification of mechanisms or compounds that can drive lysosome fission may 350 prove useful to rescue autophagic flux, degradative capacity, and lysosome dynamics in cells 351 exhibiting reduced PtdIns(3,5)P<sub>2</sub> levels. Such mechanisms or compounds may act to up-regulate 352 PtdIns(3,5)P<sub>2</sub> levels in conditions of insufficient PIKfyve activity like those caused by null-353 mutations in the Fig4 lipid phosphatase [29]. For example, the cyclin/cyclin-dependent kinase, 354 Pho80/Pho85, phosphorylates Fab1 to upregulate the levels of  $PtdIns(3,5)P_2$  in response to 355 hypertonic shock, protecting yeast cells from osmotic shock [62,63]. Alternatively, activating 356 mechanisms downstream of  $PtdIns(3,5)P_2$  that enable lysosome fission directly may also rescue 357 lysosome dynamics.

358 We previously observed that photo-toxicity during live-cell imaging with spinning disc 359 confocal microscopy prevented lysosome coalescence during apilimod-mediated PIKfyve 360 inhibition [30]. While unfortunately blunting our ability to perform high spatio-temporal resolution 361 of lysosome enlargement by live-cell imaging, we questioned if other sources of ROS could also 362 prevent lysosome coalescence during PIKfyve inhibition. Indeed, we provide evidence here that 363 ROS generated by diverse approaches can counteract and even reverse lysosome coalescence 364 during PIKfyve inhibition. Notably, neither H<sub>2</sub>O<sub>2</sub> or rotenone rescued lysosome size by up-365 regulating the levels of  $PtdIns(3,5)P_2$ . This suggests that ROS counteract lysosome coalescence by

366 acting downstream of  $PtdIns(3,5)P_2$ , or by stimulating parallel processes that promote lysosome 367 fission or impair lysosome fusion. Notably, ROS agents alone did not appreciably alter basal 368 lysosome properties like lysosome size and number. This may partially relate to resolution limit 369 of light microscopy as we estimate the radius of intact lysosomes to be 0.7  $\mu$ m, or due to physical 370 constraints of lysosomes that prevent smaller average lysosome size, or perhaps because the 371 mechanisms responsible for basal lysosome dynamics are insensitive to ROS effects. Collectively, 372 our work suggests that ROS prevent lysosome enlargement during PIKfyve inhibition, but exact 373 mode of action may depend on ROS type, and/or mode of production, and/or location since  $H_2O_2$ 374 had distinct effects from those by CDNB/auranofin, MCB and rotenone.

375 We previously showed that disrupting the microtubule system with nocodazole or 376 impairing motor proteins abated lysosome coalescence during PIKfyve inhibition [30]. Thus, we 377 explored whether ROS agents disrupted lysosome motility, which would impair fusogenicity. We 378 observed that only H<sub>2</sub>O<sub>2</sub> significantly arrested lysosome motility and reduced fusogenicity. In 379 addition, we also saw a more defined microtubule network in H<sub>2</sub>O<sub>2</sub>-treated cells, suggesting that 380 microtubules were stabilized by H<sub>2</sub>O<sub>2</sub>. Whether this effect is generalizable is debatable since there 381 are contradictory observations about the effect of H<sub>2</sub>O<sub>2</sub> on the microtubule system, which may 382 depend on cell type and experimental conditions employed [64-66]. Regardless, microtubule 383 stabilization is not sufficient to impair lysosome motility since paclitaxel did not prevent lysosome 384 enlargement caused by apilimod or impair lysosome motility. Thus, we propose that  $H_2O_2$  impairs 385 lysosome motility by disrupting motor activity, and/or impairing motor interactions with 386 lysosomes and/or microtubules. Mitochondria may offer some insight since their motility was also 387 arrested by H<sub>2</sub>O<sub>2</sub> [65]. H<sub>2</sub>O<sub>2</sub> stimulated p38a MAPK, which then interrupted motor adaptor 388 complex function. Motors themselves retained their activity since forced anchorage of kinesin to

389 mitochondria maintained mitochondrial motility in the presence of H<sub>2</sub>O<sub>2</sub> [65]. Thus, H<sub>2</sub>O<sub>2</sub> may 390 disrupt kinesin and/or dynein adaptors like RILP-ORP1L-dynein or SKIP-kinesin, though our 391 work suggests that this is not likely occurring by altering GTP-Rab7 and Arl8b loading onto 392 lysosomes.

In comparison to H<sub>2</sub>O<sub>2</sub>, ROS produced by mitochondrial uncoupling (rotenone) or amassed 393 394 by disrupting catalase and thioredoxin (MCB and CDNB/auranofin) partially depolymerized the 395 microtubule system under the employed conditions, though not sufficiently enough to hinder 396 lysosome motility. Instead, these agents may prevent overt lysosome coalescence by releasing a 397 dense F-actin network that assembles on lysosomes during PIKfyve inhibition. Consistent with 398 this, actin depolymerizers also reduced lysosome coalescence during acute PIKfyve inhibition and 399 accelerated lysosome fragmentation during PIKfyve reactivation. These observations may be 400 consistent with those by Hong *et al.*, wherein  $PtdIns(3,5)P_2$  modulates branched actin dynamics 401 on endosomes (markers apply to lysosomes as well) by regulating cortactin [21]. The authors 402 showed that PIKfyve inhibition increased actin density on endo/lysosomes, which consequently 403 impaired fission and caused enlargement [21]. Additionally, PIKfyve was recently shown to 404 modulate branched F-actin to help drive melanosome maturation [58]. Indeed, branched F-actin 405 has emerged as a major player in membrane fission for endo/lysosomes nucleated by ERendo/lysosomes contact sites [67,68]. Thus, we propose that ROS generated by rotenone, 406 407 CDNB/auranofin, and perhaps MCB, may abate lysosome coalescence by relieving dense F-actin 408 networks that form on lysosomes during PIKfyve inhibition.

While oxidative stress in cells can hinder lysosome coalescence during PIKfyve inhibition and accelerate lysosome fragmentation during PIKfyve reactivation, the exact mechanisms of action depends on the type of ROS and/or mode of production. Of the treatments we employed, 412  $H_2O_2$  was able to produce cytosolic and mitochondrial superoxide  $O_2^-$  and OH radicals, but no 413 detectable levels of singlet O<sub>2</sub> (Fig 1); likely, the ROS generated was delocalized as well. In 414 comparison, rotenone and CDNB released singlet O<sub>2</sub>, while rotenone also released mitochondrial 415 superoxide and singlet  $O_2^-$ ; neither treatment appeared to produce OH radicals (Fig. 1). We 416 propose that the likely delocalized release of ROS and OH generated by H<sub>2</sub>O<sub>2</sub> may stabilize 417 microtubules and impair motor dynamics, which then impinges on lysosome dynamics [69–71]. 418 In comparison, mitochondrial  $O_2^-$  and singlet  $O_2^-$  increases turnover of the lysosomal F-actin 419 network to shift lysosome dynamics towards fission. While we could not detect specific ROS in 420 MCB, MCB interacts with GSH and with thiol residues of other enzymes such as thioredoxin 421 reductase, leading to increased  $O_2^{-1}$  production [41,70,72]. Overall, future work should aim to better 422 delineate the type of ROS and their exact target that alter lysosome dynamics. Moreover, since 423 ROS can serve as physiological signals [37,73], it is tempting to suggest that particular ROS may 424 play a role in coordinating localized processes like membrane fusion, motor activity, and 425 membrane fission. This process or the sensors engaged by ROS may represent approaches to 426 rescue lysosome dynamics in conditions of PtdIns(3,5)P<sub>2</sub> insufficiency.

427

### 428 Materials and Methods

### 429 Cell culture, plasmids, and transfection

RAW 264.7 macrophages and HeLa cells were grown in Dulbecco's Modified Eagle Medium
(DMEM; Wisent, St Bruno, QC) supplemented with 5% heat-inactivated fetal bovine serum (FBS;
Wisent). ARPE-1 (RPE) cells stably expressing clathrin light chain-eGFP were grown in
DMEM/F12 medium (Gibco) supplemented with 10% FBS [74]. All cells were grown at 5% CO<sub>2</sub>

434	and 37 °C and routinely checked for contamination. FuGene HD (Promega, Madison, WI) was
435	used for transient transfections following manufacturer's instructions with a ratio of 3:1 FuGene
436	HD transfection reagent ( $\mu$ l) to DNA ( $\mu$ g). The transfection mixture was replaced with fresh
437	complete medium 4-5 h post-transfection and cells were used 24 h following transfection. RAW
438	cells were transfected with plasmids expressing Rab7-RILPC33-GFP (RILPC33-GFP), or wild-
439	type Arl8b-GFP (Arl8bWT-GFP), previously described in [13,75], or Galectin-3-GFP (Addgene;
440	[48]). The bacterial expression vector pZsGreen (Takara Bio USA, Inc., formerly Clontech
441	Laboratories, Inc., 632446) was transformed into E. coli DH5 $\alpha$ to generate ZsGreen-expressing
442	bacteria.

443

### 444 **Pharmacological treatment of cells**

Apilimod (Toronto Research Chemicals, Toronto, ON) was used at 20 nM for 40 min, unless 445 446 otherwise indicated, to deplete cellular PtdIns(3,5)P2. H2O2 (Bio Basic, Markham, ON) was used 447 indicated. 1-chloro-2,4,-dinitrobenzene as Rotenone. (CDNB), auranofin. and 448 monocholorobimane (MCB; Sigma-Aldrich, all from Sigma-Aldrich, Oakville, ON) were used as 449 indicated to generate ROS by respectively inhibiting mitochondrial respiratory chain complex, 450 glutathione, or thioredoxin reductase (CDNB and auranofin). Bovine liver catalase (Sigma-451 Aldrich) and N-acetyl-L-cysteine (NAC) (Bio Basic) were used as anti-oxidants. Paclitaxel and 452 nocadozole (both from Sigma-Aldrich) were used at 1 or 10 µM and 5 or 10 µM to stabilize and 453 depolymerize microtubules, respectively. Latrunculin A (Abcam, Toronto, ON) and cytochalasin 454 D (EMD Millipore, Toronto, ON) were used at 1  $\mu$ M and 5  $\mu$ M, respectively to depolymerize 455 actin. Ikarugamycin (Sigma-Aldrich) and dyngo-4A (Abcam, Cambridge, MA) used to inhibit 456 clathrin and dynamin respectively. BAPTA-AM (Sigma-Aldrich) was used to chelate intracellular

457 calcium and Fluo4-AM (ThermoFisher, Burlington, ON) was used as a fluorescent Ca<sup>2+</sup> probe. As
458 a positive control for lysosome damage, we treated cells for 2 h with 0.5 mM L-leucyl-L-leucine
459 methyl ester (LLOMe; L7393, Sigma-Aldrich).
460

### 461 Lysosome labelling

462 Lysosomes were labelled by incubating cells with 200 µg/mL Alexa<sup>546</sup>-conjugated dextran or with 463 200 µg/mL Alexa<sup>488</sup>-conjugated dextran (Thermo Fisher Scientific, Mississauga, ON) or with 2.5 464 mg/mL Lucifer yellow (Thermo Fisher Scientific, Mississauga, ON) for 2 h in complete media at 465 37 °C in 5% CO<sub>2</sub>. Cells washed with phosphate-buffered saline (PBS) and resupplied with 466 complete cell-specific media for 1 h to chase the fluid-phase marker to lysosomes before 467 pharmacological manipulation and live-cell imaging. We note that we use "lysosomes" to 468 represent a potential mixture of late endosomes, lysosomes and endolysosomes (Bright et al., 1997; 469 Choy et al., 2018). Lysosomal calcium was labelled with Fluo-4AM 8 µM by pulsing for 45 min 470 in complete media at 37 °C in 5% CO<sub>2</sub>, followed by washing with PBS and addition of complete 471 media for 45 min to chase the marker to lysosomes.

472

### 473 Live- and fixed-cell spinning disc confocal microscopy

474 Microscopy and imaging were done with a Quorum DisKovery spinning disc confocal microscope 475 system equipped with a Leica DMi8 microscope connected to an iXON 897 EMCCD camera, 476 controlled by Quorum Wave FX powered by MetaMorph software, using 63x 1.4 NA oil-477 immersion objective (Quorum Technologies, Guelph, ON). Live-cell imaging was performed 478 using environmental chamber set to 5% CO<sub>2</sub> and 37 °C in complete cell-specific medium. Standard 479 excitation and emission filter sets and lasers were used for all fluorophores. RAW and HeLa cells, unless otherwise indicated, were imaged as z-projections of 45-55 z-planes with 0.3 µm distance
between each plane, or 20-30 z-planes with 0.3 µm distance between each plane for RPE cells, as
acquired by spinning disc confocal microscopy. For time-lapse imaging, RAW cells were imaged
using single, mid-section z-plane every 4 s for 3 min. RPE cells were imaged using single, midsection z-plane every 8 s for 6 min. Clathrin-eGFP expressing RPE cells were imaged every 2 min
for 40 min.

486

### 487 **Detection of ROS production**

488 For determining intracellular net ROS production, we incubated RAW 264.7 macrophages with 5

489 µM of the cell-permeable redox sensitive dye, CellROX Green (Thermo Fisher Scientific), for 30

490 min at 37 °C with 5% CO<sub>2</sub> in the dark during treatment with various ROS producing agents.

491 Cells were washed twice with PBS followed by replenishment with complete media and

492 imaging. To detect specific intracellular ROS, we used several probes: hydroxylphenyl

493 fluorescein to detect hydroxyl radical and peroxynitrite (HPF; Thermo Fisher Scientific),

494 MitoSOX Red for mitochondrial superoxide (Thermo Fisher Scientific), Biotracker Si-DMA for

495 singlet oxygen (Millipore Sigma), and ROS-ID detection kit (Enzo Life Sciences) for general

496 superoxide. After treatment with ROS inducers, cells were washed with PBS 3x before adding

497 these fluorescent probes. Cells were incubated with 5 µM Mitosox Red for 10 min at 37 °C with

498 5% CO<sub>2</sub> in the dark, or 100 nM Si-DMA or 10 µM HPF for 45 minutes. For ROS-ID 0.06 nM

499 ROS-ID was added 1 h before, incubated at 37 °C with 5% CO<sub>2</sub> in the dark, followed by washing

500 with PBS and adding ROS inducers. After treatment with ROS probes or inducers, cells were

- 501 washed 3x PBS and supplemented with probe specific media. All experiments were imaged
- 502 using live-cell spinning disc confocal microscopy as described.

### 503 Immunofluorescence and F-actin imaging

504 Following experimentation, cells were fixed for 15 min with 4% (v/v) paraformaldehyde in PBS, 505 permeabilized for 10 min with 0.1% Triton X-100 (v/v) in PBS, and then blocked with 3% BSA 506 (v/v) in PBS. Subsequently, cells were incubated with mouse monoclonal antibody against  $\alpha$ -507 tubulin (1:200; Sigma-Aldrich), followed by incubation with donkey Dylight-conjugated 508 polyclonal antibody against mouse IgG (1:1000; Bethyl), and samples were then mounted in Dako 509 mounting media for subsequent imaging. Alternatively, lysosomes were labelled with Alexa<sup>488</sup>-510 conjugated dextran as before, followed by fixation for 15 min with 4% (v/v) paraformaldehyde, 511 permeabilized for 10 min with 10 µg/ml digitonin (Promega, Madison, WI), and blocked with 3% 512 BSA (v/v), all solutions in PBS. Cells were then stained for F-actin with fluorescent-phalloidin 513 (ThermoFisher Scientific).

### 514 Lysosome damage detected by galectin-3-GFP

515 RAW cells were seeded in DMEM supplemented with 5% FBS for 24 h at 37 °C in 5% CO<sub>2</sub>. Cells 516 were transfected with Galectin-3-GFP plasmid (0.5  $\mu$ g) using FuGene HD (Promega, Madison, 517 WI) with a ratio of 3:1 for 24 h at 37 °C in 5% CO<sub>2</sub>. Post-transfection, cells were treated with 1 518 mM H<sub>2</sub>O<sub>2</sub> for 40 min, 1  $\mu$ M rotenone for 60 min or for 2 h with 0.5 mM L-leucyl-L-leucine methyl 519 ester (LLOMe; L7393, Sigma-Aldrich). 520

### 521 Image analysis

522 To determine lysosome number, individual lysosome volume and total cellular lysosome volume, 523 we used Volocity (Volocity 6.3.0) particle detection and volumetric tools. Z-stack images were 524 imported into Volocity and a signal threshold was applied at 2x the average cytosolic fluorescence 525 intensity. Particles were defined as being greater than 0.3 µm<sup>3</sup> for inclusion into the analysis, and 526 if necessary, a watershed function was applied to split lysosome aggregates caused by 527 thresholding. Regions of interest were drawn surrounding individual cells for cell-to-cell analysis. 528 Lysosome speed, track length, and displacement were assessed using Imaris (BitPlane, Concord, 529 MA) with 'ImarisTrackLineage' module.

530 To determine the level of membrane-bound RILP-C33 and Arl8b, we estimated the membrane-bound to cytosolic ratio of fluorescently-tagged proteins. Using ImageJ, lines that were 531 532 3-pixel wide by 20-40-pixel long were assigned to areas of transfected cells using a predetermined 533 grid to avoid bias but excluding the nucleus. Plot profiles were then obtained, exported into an 534 Excel spreadsheet, values were arranged according to fluorescence intensity, and the ratio 535 calculated for highest 10 pixels over lowest 10 pixels along the length of the line (FH/FL 536 fluorescence ratio); the expectation is that values approximate to 1 represent low membrane signal 537 due to mostly cytosolic signal, while ratio values greater than 1 represent signal that localizes to 538 punctate structures relative to cytosol (Chintaluri et al., 2018).

539 For determination of clathrin-GFP on lysosomes, RPE cells stably expressing clathrin 540 heavy chain-eGFP were loaded with Alexa<sup>546</sup>-conjugated dextran and treated with apilimod, 541 followed by imaging with spinning disc confocal microscope. Image analysis was performed 542 using ImageJ by thresholding Alexa<sup>546</sup>-conjugated dextran signal and generating a mask, which 543 was then applied to the green (clathrin) channel to determine the GFP fluorescence intensity on 544 regions marked by dextran signal. Regions of interest within the cytosol and the extracellular

545 space were drawn to respectively obtain mean cytosolic fluorescence intensity and background. 546 These values were then used to calculate the ratio of lysosome-to-cytosol clathrin-eGFP. Similar approach was employed to determine Fluo-4AM intensity for dextran Alexa<sup>546</sup> lysosomal 547 548 structures over cytosolic Fluo-4AM to obtain lysosome-to-cytosol Fluo-4AM intensity ratio. To 549 determine the fluorescence of intracellular CellROX Green or other ROS probes, images were 550 imported onto Volocity (Volocity 6.3.0) or ImageJ, regions of interest were drawn around cell, 551 and mean fluorescence intensity per cell was recorded and background-corrected. For galectin-3-552 GFP analysis, images were imported into ImageJ, background-corrected, and then thresholding 553 was applied to each individual transfected cell (25-30 cells per condition) to identify galectin-3-554 GFP puncta. Particles ranging between 50-1000  $\mu$ m<sup>2</sup> were then counted, with the assumption that 555 smaller size particles corresponded to noise.

556 To assess microtubule structure, we sought to use several measures as proxies for 557 microtubule alteration under different treatments. Single-plane images were converted to 8-bit 558 images through ImageJ followed by application of fluorescence intensity threshold to select 559 microtubules. Images were converted to binary and filaments analyzed through "skeleton" and 560 "Analyzeskeleton". Total number of microtubules junctions, where junctions represent 561 filamentous pixels from where two or more microtubule branches arise, total number of 562 microtubule branches and average microtubule branch length were scored and collected for data 563 analysis. Alternatively, RPE cell microtubule structure was analyzed through applying binary filter 564 to fluorescent microtubules, followed by watershed segmentation to segregate microtubules into 565 areas of tubulin patches with the expectation that depolymerized microtubules pool into large 566 patches compared to intact tubulin.

567 Image contrast enhancement was performed with Adobe Photoshop CS (Adobe Systems,
568 San Jose, CA) or ImageJ without changing relative signals and applied after quantification. Adobe
569 Illustrator CS (Adobe Systems) was used for constructing figures.

570

### 571 Lysosome fractionation

572 RAW 264.7 cells were grown and used according to manufacturer's instructions to obtain 573 membrane fractions by differential sedimentation ultracentrifugation using a density gradient 574 (Lysosome Isolation Kit, Sigma-Aldrich, LYSISO1). Briefly, cells were lysed and homogenates 575 centrifuged 1,000 xg for 10 min at 4 °C to separate unbroken cells and debris from cytoplasmic 576 membranes. The supernatant was further centrifuged at 20,000 xg for 20 min at 4 °C to pellet 577 lysosomes and other organelles. The pellet was reconstituted with Optiprep density gradient 578 medium (60% (w/v) solution of iodixanol in water and sucrose) and loaded onto of a step-wise 579 sucrose gradient as described by the manufacturer and subjected to ultracentrifugation at 150,000 580 xg for 4 h at 4 °C using SW50.1 rotor (Beckman Coulter, Mississauga, ON). Fractions were then 581 collected and subject to denaturation with Laemmli buffer until further use.

582

### 583 Membrane fractionation

RAW cells were lysed in 200  $\mu$ l ice cold homogenization buffer (3 mM imidazole, 250 mM sucrose, 0.5 mM EDTA, pH 7.4 with protease inhibitor cocktail). Cells were homogenized by passing 10x though a 25-gauge needle, then lysates were sequentially centrifuged at 3000 *xg* for 10 min at 4 °C and 7,000 *xg* for 10 min at 4°C to clear supernantants. Supernatants were then further centrifuged at 100,000 *xg* using SORVALL wX+ULTRA-centrifuge (Thermo Scientific) for 30 min at 4°C to separate cytosol and membranes. Next, the pellets were resuspended in 0.5%

- 590 digitonin in solubilization buffer (50 mM NaCl, 50 mM imidazole, 2.5 mM 6-aminohexanoic acid,
- 591 2 mM EDTA, pH ~7) to obtain membrane-bound materials.

### 592 Western Blotting

593 For whole-cell lysates in 2x Laemmli buffer, cells were passed six times through 27-gauge needle, 594 heated. Cell lysates or cell fractions were resolved through SDS-PAGE with 10% acrylamide 595 resolving gel. Proteins were then transferred to a PVDF membrane, blocked and incubated with 596 primary and HRP-conjugated secondary antibodies in Tris-buffered saline containing 5% skimmed 597 milk and 0.1% Tween-20. Clarity enhanced chemiluminescence (Bio-Rad Laboratories, 598 Mississauga, ON) was used to visualize proteins with ChemiDoc Touch Imaging system (Bio-599 Rad). Protein quantification was performed using Image Lab software (Bio-Rad) by sequentially 600 normalizing against a loading control and against vehicle-treated condition. We used rabbit 601 polyclonal antibodies against VAPB (1:3000, HPA013144, Sigma-Aldrich) and vinculin (1:1000, 602 4650, Cell Signalling Technologies), rabbit XP® monoclonal antibodies against Rab7 (1:100, 603 D95F2, Cell Signalling Technologies), mouse monoclonal antibodies against clathrin heavy chain 604 (1:500, sc-12734, Santa Cruz Biotechnology), Arl8a/b (1:500, clone H8, Santa Cruz 605 Biotechnology), and ATP5A (1:2000, ab14748, Abcam), rat monoclonal antibodies against 606 LAMP1 (1:200-1:500, 1D4B, Developmental Studies Hybridoma Bank, Iowa City, IO or Santa 607 Cruz Biotechnology), and goat polyclonal antibody against dynamin 2 (1:1000, sc-6400, Santa 608 Cruz Biotechnology). Secondary antibodies were raised in donkey (Bethyl) and HRP-conjugated. 609

# Phosphoinositide labelling with <sup>3</sup>H-myo-inositol and HPLC-coupled flow scintillation

612 RAW cells were incubated for 24 h with inositol-free DMEM (MP Biomedica, CA) containing 10 613  $\mu$ Ci/ml myo-[2-<sup>3</sup>H(N)] inositol (Perkin Elmer, MA), 1X insulin-transferrin-selenium-614 ethanolamine (Gibco), 10% dialyzed FBS (Gibco), 4 mM L-glutamine (Sigma-Aldrich) and 20 615 mM HEPES (Gibco). Cells were then treated with rotenone,  $H_2O_2$  and/or apilimod as indicated. 616 Cells were lysed and lipids precipitated with 600  $\mu$ l of 4.5% perchloric acid (v/v) for 15 min on 617 ice, collected by scraping and pellet obtained at 12000 xg for 10 min. Then, 1 ml of 0.1 M EDTA 618 was used to wash pellets followed by resuspension in 50  $\mu$ l water. This was followed by 500  $\mu$ l of 619 methanol/40% methylamine/1-butanol [45.7% methanol: 10.7% methylamine: 11.4% 1-butanol 620 (v/v)] used for 50 min at 53 °C to deacylate phospholipids. Sample pellets were vaccum-dried and 621 washed twice in 300 µl water with vaccum-drying. Deacylated phospholipids were extracted from 622 dried sample pellets by resuspending pellet in 450 µl water and 300 µl 1-butanol/ethyl ether/ethyl 623 formate (20:4:1), vortexing 5 min, followed by centrifugation 12000 xg for 2 min and then the 624 bottom aqueous layer was collected. Extraction was performed three times followed by vaccum-625 drying the aqueous layer and resuspending lipids in 50  $\mu$ l water. For all treatment samples, equal 626 <sup>3</sup>H counts were loaded and separated by HPLC (Agilent Technologies, Mississauga, ON) through 627 4.6 x 250-mm anion exchange column (Phenomenex, Torrance, CA) using a 1 ml/min flow rate 628 with a gradient set with water (buffer A) and 1 M (NH<sub>4</sub>)<sub>2</sub>HPO<sub>4</sub>, pH 3.8 (phosphoric acid adjusted) 629 (buffer B) as follows: 0% B for 5 min, 0 to 2% B for 15 minutes, 2% B for 80 minutes, 2 to 10% 630 B for 20 minutes, 10% B for 30 minutes, 10 to 80% B for 10 minutes, 80% B for 5 minutes, 80 to 631 0% B for 5 minutes. Radiolabel signal was detected with a 1:2 ratio of eluate to scintillant 632 (LabLogic, Brandon, FL) in a  $\beta$ -RAM 4 (LabLogic) and analyzed by Laura 4 software. Each

phosphoinositide species detected was normalized against the parent phosphatidylinositol peak asdescribed in (Ho et al., 2016).

635

Phagocytosis particle preparation and phagosome maturation assays 636 637 pZsGreen-containing bacteria were grown at 37 °C in Lysogeny Broth (LB), supplemented with 638 1% glucose to suppress leaky ZsGreen expression, and 100 µg/mL ampicillin (LB Growth Media). 639 To produce ZsGreen-expressing bacteria, bacteria cultures were grown overnight in liquid LB 640 Growth Media. The bacteria culture was then subcultured 1:100 in LB supplemented with 641 ampicillin and without glucose (LB Expression Media) and incubated at 37 °C to mid-log growth 642 phase. Isopropylthio-β-galactoside was added into the subculture to a final concentration of 100 643 µM, and the subculture was incubated for another 3 hours. Bacteria were washed with PBS, then 644 fixed with 4% PFA, and stored at 4 °C in PFA. Prior to use, fixed bacteria were washed with PBS 645 to remove PFA.

646 RAW macrophages at 30 to 60% confluence were treated with 1 mM H<sub>2</sub>O<sub>2</sub> or 0.1% ddH<sub>2</sub>O (vehicle control) for 1 h. Subsequently,  $8.0 \times 10^7$  bacteria (0.1 OD  $\times$  1 mL) were introduced to 647 648 macrophages and centrifuged at 400 x g for 5 minutes to synchronize phagocytosis. Macrophages 649 were incubated for 20 minutes in the presence of  $H_2O_2$  or ddH<sub>2</sub>O before washing with PBS and 650 incubating in media containing H<sub>2</sub>O<sub>2</sub> or ddH<sub>2</sub>O for 40 minutes. Except for PBS wash, macrophage 651 exposure to  $H_2O_2$  was uninterrupted. Macrophages were washed with PBS then fixed with 4% 652 PFA. Cells were then incubated in 1% w/v glycine to quench PFA. Cells were then blocked with 653 1% Bovine Serum Albumin (BSA), then external bacteria were immunolabeled with rabbit anti-654 E. coli antibodies (1:100, Bio-Rad Antibodies, 4329-4906), followed by DyLight 650-conjugated 655 donkey anti-rabbit IgG antibodies (1:1000, Bethyl Laboratories, Inc., A120-208D5). Cells were

656	then permeabilized with ice-cold methanol and blocked with 1% BSA. LAMP-1 lysosomal marker
657	protein was immunolabeled with rat anti-LAMP-1 antibodies (1:100, 1D4B, Developmental
658	Studies Hybridoma Bank, Iowa City, IO), followed by DyLight 550-conjugated donkey anti-rat
659	IgG antibodies (1:1000, Bethyl Laboratories, Inc., A110-337D3). Coverslips were mounted with
660	Dako Fluorescence Mounting Medium (Agilent, S302380-2) for imaging.
661	FIJI was used for image processing and quantitative image analysis of phagosome
662	maturation. Internal bacteria masks were produced by applying a subtraction mask using external

bacteria signal. "Noise" particles defined as being a few pixels in size were removed manually.

The internal bacteria mask was converted to binary and dilated to reach the edges of the phagosomes (LAMP1 signal). LAMP-1 signal colocalized to the internal bacteria mask was analyzed cell-by-cell, and the mean LAMP-1 fluorescence intensity per cell was obtained.

667

### 668 Statistical analysis

All experiments were performed independently at least three times. Respective figure legends indicate number of cells/samples assessed, mean, standard error of mean (s.e.m.) and number of independent experiments. For analysing significant difference between various treatment groups, we used unpaired Student's t-test when comparing two groups only or one-way ANOVA test when comparing multiple treatment conditions in non-normalized controls. Tukey's *post hoc* test coupled to ANOVA tests was used to evaluate pairwise conditions. Statistical significance was defined as P>0.05. Software used for analysis was GraphPad Prism 8.

676

## 677 **References**

- Luzio JP, Rous BA, Bright NA, Pryor PR, Mullock BM, Piper RC. Lysosome-endosome
   fusion and lysosome biogenesis. J Cell Sci. 2000;113 (Pt 9: 1515–24. Available: http://www.ncbi.nlm.nih.gov/pubmed/10751143
- Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol.
  2007;8: 622–32. doi:10.1038/nrm2217
- Bu J, Guardia CM, Keren-Kaplan T, Bonifacino JS. Mechanisms and functions of lysosome positioning. J Cell Sci. Company of Biologists; 2016;129: 4329–4339.
  doi:10.1242/jcs.196287
- 686 4. Bissig C, Hurbain I, Raposo G, van Niel G. PIKfyve activity regulates reformation of
  687 terminal storage lysosomes from endolysosomes. Traffic. 2017;18: 747–757.
  688 doi:10.1111/tra.12525
- 689 5. Bright NA, Reaves BJ, Mullock BM, Luzio JP. Dense core lysosomes can fuse with late
  690 endosomes and are re-formed from the resultant hybrid organelles. J Cell Sci. 1997;110 (
  691 Pt 1: 2027–40. Available: http://www.ncbi.nlm.nih.gov/pubmed/9378754
- 6. Bright NA, Davis LJ, Luzio JP. Endolysosomes Are the Principal Intracellular Sites of Acid
  693 Hydrolase Activity. Curr Biol. Elsevier; 2016;26: 2233–45. doi:10.1016/j.cub.2016.06.046
- 694 7. Perou CM, Leslie JD, Green W, Li L, Ward DM, Kaplan J. The Beige/Chediak-Higashi
  695 syndrome gene encodes a widely expressed cytosolic protein. J Biol Chem. 1997;272:
  696 29790–4. Available: http://www.ncbi.nlm.nih.gov/pubmed/9368050
- 8. Bright NA, Gratian MJ, Luzio JP. Endocytic delivery to lysosomes mediated by concurrent
  fusion and kissing events in living cells. Curr Biol. 2005;15: 360–365.
  doi:10.1016/j.cub.2005.01.049
- Duclos S, Corsini R, Desjardins M. Remodeling of endosomes during lysosome biogenesis
  involves "kiss and run" fusion events regulated by rab5. J Cell Sci. 2003;116: 907–18.
  Available: http://www.ncbi.nlm.nih.gov/pubmed/12571288
- Saffi GT, Botelho RJ. Lysosome Fission: Planning for an Exit [Internet]. Trends in Cell
  Biology. 2019. pp. 635–646. doi:10.1016/j.tcb.2019.05.003
- 11. Khatter D, Raina VB, Dwivedi D, Sindhwani A, Bahl S, Sharma M. The small GTPase
  Arl8b regulates assembly of the mammalian HOPS complex on lysosomes. J Cell Sci.
  2015;128: 1746–61. doi:10.1242/jcs.162651
- Wang T, Ming Z, Xiaochun W, Hong W. Rab7: Role of its protein interaction cascades in endo-lysosomal traffic [Internet]. Cellular Signalling. 2011. pp. 516–521. doi:10.1016/j.cellsig.2010.09.012
- 711 13. Cantalupo G, Alifano P, Roberti V, Bruni CB, Bucci C. Rab-interacting lysosomal protein
  712 (RILP): The Rab7 effector required for transport to lysosomes. EMBO J. 2001;20: 683–
  713 693. doi:10.1093/emboj/20.4.683
- Pankiv S, Alemu E a., Brech A, Bruun J-AA, Lamark T, Øvervatn A, et al. FYCO1 is a
  Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end Directed vesicle
  transport. J Cell Biol. 2010;188: 253–269. doi:10.1083/jcb.200907015
- 717 15. Rosa-Ferreira C, Munro S. Arl8 and SKIP Act Together to Link Lysosomes to Kinesin-1.
  718 Dev Cell. 2011;21: 1171–1178. doi:10.1016/j.devcel.2011.10.007
- 719 16. Khatter D, Sindhwani A, Sharma M. Arf-like GTPase Arl8: Moving from the periphery to
  720 the center of lysosomal biology. Cell Logist. 2015;5: e1086501.
  721 doi:10.1080/21592799.2015.1086501
- 17. Luzio JP, Parkinson MDJ, Gray SR, Bright NA. The delivery of endocytosed cargo to

723 lysosomes. Biochem Soc Trans. 2009;37: 1019–1021. doi:10.1042/BST0371019

- 18. Cao Q, Zhong XZ, Zou Y, Murrell-Lagnado R, Zhu MX, Dong XP. Calcium release through
  P2X4 activates calmodulin to promote endolysosomal membrane fusion. J Cell Biol.
  2015;209: 879–894. doi:10.1083/jcb.201409071
- 19. Cao Q, Yang Y, Zhong XZ, Dong XP. The lysosomal Ca2+release channel TRPML1
  regulates lysosome size by activating calmodulin. J Biol Chem. 2017;292: 8424–8435.
  doi:10.1074/jbc.M116.772160
- Fang X, Zhou J, Liu W, Duan X, Gala U, Sandoval H, et al. Dynamin Regulates Autophagy
  by Modulating Lysosomal Function. J Genet Genomics. 2016;43: 77–86.
  doi:10.1016/j.jgg.2015.10.005
- Hong NH, Qi A, Weaver AM. PI(3,5)P2 controls endosomal branched actin dynamics by
  regulating cortactin-Actin interactions. J Cell Biol. 2015;210: 753–769.
  doi:10.1083/jcb.201412127
- Renvoisé B, Chang J, Singh R, Yonekawa S, FitzGibbon EJ, Mankodi A, et al. Lysosomal
  abnormalities in hereditary spastic paraplegia types SPG15 and SPG11. Ann Clin Transl
  Neurol. 2014;1: 379–389. doi:10.1002/acn3.64
- Rong Y, Liu M, Ma L, Du W, Zhang H, Tian Y, et al. Clathrin and phosphatidylinositol4,5-bisphosphate regulate autophagic lysosome reformation. Nat Cell Biol. 2012;14: 924–
  934. doi:10.1038/ncb2557
- 742 24. Traub LM, Bannykh SI, Rodel JE, Aridor M, Balch WE, Kornfeld S. AP-2-containing
  743 clathrin coats assemble on mature lysosomes. J Cell Biol. 1996;135: 1801–14. Available:
  744 http://www.ncbi.nlm.nih.gov/pubmed/8991092
- Li X, Rydzewski N, Hider A, Zhang X, Yang J, Wang W, et al. A molecular mechanism to
  regulate lysosome motility for lysosome positioning and tubulation. Nat Cell Biol. 2016;18:
  404–417. doi:10.1038/ncb3324
- Yang Y, Xu M, Zhu X, Yao J, Shen B, Dong X-P. Lysosomal Ca2+ release channel
  TRPML1 regulates lysosome size by promoting mTORC1 activity. Eur J Cell Biol.
  2019;98: 116–123. doi:10.1016/j.ejcb.2019.05.001
- 751 27. McCartney AJ, Zhang Y, Weisman LS. Phosphatidylinositol 3,5-bisphosphate: low abundance, high significance. Bioessays. 2014;36: 52–64. doi:10.1002/bies.201300012
- Shisheva A, Sbrissa D, Ikonomov O. Plentiful PtdIns5P from scanty PtdIns(3,5)P<sub>2</sub> or from ample PtdIns? PIKfyve-dependent models: Evidence and speculation (response to: DOI 10.1002/bies.201300012). BioEssays. 2015;37: 267–277. doi:10.1002/bies.201400129
- Chow CY, Zhang Y, Dowling JJ, Jin N, Adamska M, Shiga K, et al. Mutation of FIG4
  causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature.
  2007;448: 68–72. doi:10.1038/nature05876
- Choy CH, Saffi G, Gray MA, Wallace C, Dayam RM, Ou Z-YA, et al. Lysosome
  enlargement during inhibition of the lipid kinase PIKfyve proceeds through lysosome
  coalescence. J Cell Sci. 2018; jcs.213587. doi:10.1242/jcs.213587
- 762 Sbrissa D, Ikonomov OC, Fu Z, Ijuin T, Gruenberg J, Takenawa T, et al. Core protein 31. 763 machinery for mammalian phosphatidylinositol 3,5-bisphosphate synthesis and turnover 764 that regulates the progression of endosomal transport: Novel Sac phosphatase joins the 765 ArPIKfyve-PIKfyve complex. J Biol Chem. 2007;282: 23878-23891. 766 doi:10.1074/jbc.M611678200
- Gopaldass N, Fauvet B, Lashuel H, Roux A, Mayer A. Membrane scission driven by the
  PROPPIN Atg18. EMBO J. 2017;36: e201796859. doi:10.15252/embj.201796859

- Chen Y, Azad MB, Gibson SB. Superoxide is the major reactive oxygen species regulating
  autophagy. Cell Death Differ. 2009;16: 1040–1052. doi:10.1038/cdd.2009.49
- 34. Dizdaroglu M, Jaruga P. Mechanisms of free radical-induced damage to DNA. Free Radic
  Res. 2012;46: 382–419. doi:10.3109/10715762.2011.653969
- Finkel T. From Sulfenylation to Sulfhydration: What a Thiolate Needs to Tolerate. Sci
  Signal. 2012;5: pe10–pe10. doi:10.1126/scisignal.2002943
- Ristow M, Schmeisser S. Extending life span by increasing oxidative stress. Free Radic Biol
  Med. 2011;51: 327–336. doi:10.1016/j.freeradbiomed.2011.05.010
- 37. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol.
  NIH Public Access; 2014;24: R453-62. doi:10.1016/j.cub.2014.03.034
- 38. Marengo B, Nitti M, Furfaro AL, Colla R, Ciucis C De, Marinari UM, et al. Redox homeostasis and cellular antioxidant systems: Crucial players in cancer growth and therapy [Internet]. Oxidative Medicine and Cellular Longevity. Hindawi Limited; 2016. p. 6235641. doi:10.1155/2016/6235641
- 39. Icha J, Weber M, Waters JC, Norden C. Phototoxicity in live fluorescence microscopy, and
  how to avoid it. BioEssays. 2017;39: 1700003. doi:10.1002/bies.201700003
- 40. Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H.
  Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the
  Context of Pharmacological and Safety Evaluation. Sci Rep. Nature Publishing Group;
  2017;7: 45465. doi:10.1038/srep45465
- Kamencic H, Lyon A, Paterson PG, Juurlink BHJ. Monochlorobimane Fluorometric
  Method to Measure Tissue Glutathione. Anal Biochem. 2000;286: 35–37.
  doi:10.1006/abio.2000.4765
- Padgaonkar VA, Leverenz VR, Bhat A V, Pelliccia SE, Giblin FJ. Thioredoxin reductase
  activity may be more important than GSH level in protecting human lens epithelial cells
  against UVA light. Photochem Photobiol. NIH Public Access; 2015;91: 387–96.
  doi:10.1111/php.12404
- Aldini G, Altomare A, Baron G, Vistoli G, Carini M, Borsani L, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018;52: 751–762. doi:10.1080/10715762.2018.1468564
- 44. Lee SR, Kwon KS, Kim SR, Rhee SG. Reversible inactivation of protein-tyrosine
  phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem.
  1998;273: 15366–72. Available: http://www.ncbi.nlm.nih.gov/pubmed/9624118
- 45. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. European Molecular Biology Organization; 2003;22: 5501–5510. doi:10.1093/emboj/cdg513
- 46. Ho CY, Choy CH, Botelho RJ. Radiolabeling and Quantification of Cellular Levels of
  Phosphoinositides by High Performance Liquid Chromatography-coupled Flow
  Scintillation. J Vis Exp. 2016; e53529–e53529. doi:10.3791/53529
- Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. American Society for
  Cell Biology; 2014;25: 2677–81. doi:10.1091/mbc.E14-04-0916
- 48. Maejima I, Takahashi A, Omori H, Kimura T, Takabatake Y, Saitoh T, et al. Autophagy
  sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO
  J. EMBO J; 2013;32: 2336–2347. doi:10.1038/emboj.2013.171
- 49. Chauhan S, Kumar S, Jain A, Ponpuak M, Mudd MH, Kimura T, et al. TRIMs and Galectins
  814 Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane

815 Damage Homeostasis. Dev Cell. 2016;39: 13–27. doi:10.1016/j.devcel.2016.08.003

- 50. Dong X, Shen D, Wang X, Dawson T, Li X, Zhang Q, et al. PI(3,5)P(2) controls membrane
  trafficking by direct activation of mucolipin Ca(2+) release channels in the endolysosome.
  Nat Commun. 2010;1: 38. doi:10.1038/ncomms1037
- S1. Zhang X, Cheng X, Yu L, Yang J, Calvo R, Patnaik S, et al. MCOLN1 is a ROS sensor in
  lysosomes that regulates autophagy. Nat Commun. 2016;7: 12109.
  doi:10.1038/ncomms12109
- 52. Dayam RM, Saric A, Shilliday RE, Botelho RJ. The Phosphoinositide-Gated Lysosomal
  Ca2+ Channel, TRPML1, Is Required for Phagosome Maturation. Traffic. 2015;16: 1010–
  1026. doi:10.1111/tra.12303
- S3. Gee KR, Brown KA, Chen WNU, Bishop-Stewart J, Gray D, Johnson I. Chemical and physiological characterization of fluo-4 Ca2+-indicator dyes. Cell Calcium. Elsevier Ltd;
  2000;27: 97–106. doi:10.1054/ceca.1999.0095
- 828 54. Boutry M, Branchu J, Lustremant C, Pujol C, Pernelle J, Matusiak R, et al. Inhibition of
  829 Lysosome Membrane Recycling Causes Accumulation of Gangliosides that Contribute to
  830 Neurodegeneration. Cell Rep. 2018;23: 3813–3826. doi:10.1016/j.celrep.2018.05.098
- 831 55. Elkin SR, Oswald NW, Reed DK, Mettlen M, MacMillan JB, Schmid SL. Ikarugamycin: A
  832 Natural Product Inhibitor of Clathrin-Mediated Endocytosis. Traffic. Blackwell
  833 Munksgaard; 2016;17: 1139–1149. doi:10.1111/tra.12425
- 56. Von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, et al. Role
  of the clathrin terminal domain in regulating coated pit dynamics revealed by small
  molecule inhibition. Cell. Cell Press; 2011;146: 471–484. doi:10.1016/j.cell.2011.06.025
- 837 57. Hoyer MJ, Chitwood PJ, Ebmeier CC, Striepen JF, Qi RZ, Old WM, et al. A Novel Class
  838 of ER Membrane Proteins Regulates ER-Associated Endosome Fission. Cell. 2018;175:
  839 254-265.e14. doi:10.1016/j.cell.2018.08.030
- Bissig C, Croisé P, Heiligenstein X, Hurbain I, Lenk GM, Kaufman E, et al. The PIKfyve complex regulates the early melanosome homeostasis required for physiological amyloid formation. J Cell Sci. 2019;132: jcs229500. doi:10.1242/jcs.229500
- 843 59. Hasegawa J, Iwamoto R, Otomo T, Nezu A, Hamasaki M, Yoshimori T. Autophagosome-844 lysosome fusion in neurons requires INPP5E, a protein associated with Joubert syndrome. 845 Molecular EMBO J. European Biology Organization; 2016;35: 1853-67. 846 doi:10.15252/embj.201593148
- Krajcovic M, Krishna S, Akkari L, Joyce JA, Overholtzer M. mTOR regulates phagosome
  and entotic vacuole fission. Klumperman J, editor. Mol Biol Cell. 2013;24: 3736–3745.
  doi:10.1091/mbc.E13-07-0408
- 61. Gan Q, Wang X, Zhang Q, Yin Q, Jian Y, Liu Y, et al. The amino acid transporter SLC36.1 cooperates with PtdIns3P 5-kinase to control phagocytic lysosome reformation. J Cell
  Biol. Rockefeller University Press; 2019;218: 2619–2637. doi:10.1083/JCB.201901074
- Cooke FT, Dove SK, McEwen RK, Painter G, Holmes a B, Hall MN, et al. The stressactivated phosphatidylinositol 3-phosphate 5-kinase Fab1p is essential for vacuole function
  in S. cerevisiae. Curr Biol. 1998;8: 1219–22. doi:10.1016/S0960-9822(07)00513-1
- Bin N, Jin Y, Weisman LS. Early protection to stress mediated by CDK-dependent PI3,5P
  2 signaling from the vacuole/lysosome. J Cell Biol. Rockefeller University Press; 2017;216:
  2075–2090. doi:10.1083/jcb.201611144
- Mackeh R, Lorin S, Ratier A, Mejdoubi-Charef N, Baillet A, Bruneel A, et al. Reactive
  oxygen species, AMP-activated protein kinase, and the transcription cofactor p300 regulate

- α-tubulin acetyltransferase-1 (αTAT-1/MEC-17)-dependent microtubule hyperacetylation
   during cell stress. J Biol Chem. American Society for Biochemistry and Molecular Biology;
   2014;289: 11816–28. doi:10.1074/jbc.M113.507400
- Bebattisti V, Gerencser AA, Saotome M, Das S, Hajnóczky G. ROS Control Mitochondrial
  Motility through p38 and the Motor Adaptor Miro/Trak. Cell Rep. Elsevier B.V.; 2017;21:
  1667–1680. doi:10.1016/j.celrep.2017.10.060
- 867
  66. Valen G, Sondén A, Vaage J, Malm E, Kjellström BT. Hydrogen peroxide induces
  868 endothelial cell atypia and cytoskeleton depolymerization. Free Radic Biol Med. Elsevier
  869 Inc.; 1999;26: 1480–1488. doi:10.1016/S0891-5849(99)00009-X
- Friedman JR, DiBenedetto JR, West M, Rowland AA, Voeltz GK. Endoplasmic reticulumendosome contact increases as endosomes traffic and mature. Hegde RS, editor. Mol Biol
  Cell. 2013;24: 1030–1040. doi:10.1091/mbc.E12-10-0733
- 873 68. Rowland AA, Chitwood PJ, Phillips MJ, Voeltz GK. ER contact sites define the position
  874 and timing of endosome fission. Cell. 2014;159: 1027–1041.
  875 doi:10.1016/j.cell.2014.10.023
- 876 Korge P, Calmettes G, Weiss JN. Increased reactive oxygen species production during 69. 877 reductive stress: The roles of mitochondrial glutathione and thioredoxin reductases. 878 Biophys Biochim Acta. NIH Public Access; 2015;1847: 514-25. doi:10.1016/j.bbabio.2015.02.012 879
- 880 70. Nordberg J, Zhong L, Holmgren A, Arnér ES. Mammalian thioredoxin reductase is 881 irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active 882 selenocysteine and its neighboring cysteine residue. J Biol Chem. American Society for 883 Biochemistry Molecular 10835-42. and Biology; 1998;273: 884 doi:10.1074/JBC.273.18.10835
- 71. Ochi R, Dhagia V, Lakhkar A, Patel D, Wolin MS, Gupte SA. Rotenone-stimulated superoxide release from mitochondrial complex I acutely augments L-type Ca<sup>2+</sup> current in A7r5 aortic smooth muscle cells. Am J Physiol Circ Physiol. 2016;310: H1118–H1128. doi:10.1152/ajpheart.00889.2015
- Lubos E, Loscalzo J, Handy DE. Glutathione peroxidase-1 in health and disease: From molecular mechanisms to therapeutic opportunities [Internet]. Antioxidants and Redox Signaling. Mary Ann Liebert, Inc.; 2011. pp. 1957–1997. doi:10.1089/ars.2010.3586
- 892 73. Brown DI, Griendling KK. Nox proteins in signal transduction [Internet]. Free Radical 893 Biology and Medicine. Free Radic Biol Med; 2009. pp. 1239–1253. 894 doi:10.1016/j.freeradbiomed.2009.07.023
- Aguet F, Antonescu CN, Mettlen M, Schmid SL, Danuser G. Advances in analysis of low signal-to-noise images link dynamin and AP2 to the functions of an endocytic checkpoint.
  Dev Cell. 2013;26: 279–291. doi:10.1016/j.devcel.2013.06.019
- Hofmann I. An N-terminally acetylated Arf-like GTPase is localised to lysosomes and affects their motility. J Cell Sci. 2006;119: 1494–1503. doi:10.1242/jcs.02958
- 900
- 901
- 902

## 903 Figure legends

904

#### 905 Figure 1: Different ROS inducers produce different ROS in RAW macrophages. (A) RAW

- 906 cells were exposed to vehicle, or to one of the following ROS inducers  $-1 \text{ mM H}_2O_2 40 \text{ min}, 1$
- 907 μM rotenone 60 min, 10 μM CDNB 30 min, or 5 μM MCB 30 min. Cells were then stained with
- 908 CellROX Green to detect and quantify the levels of ROS formed during these treatments.
- 909 Fluorescence micrographs represent single z-focal plane images from spinning disc confocal
- 910 microscopy. Scale bar =  $20 \,\mu$ m. (B) Quantification of CellROX Green fluorescence intensity. C)
- 911 MCB-GSH adduct was also detected during vehicle or MCB treatment. Fluorescence
- 912 micrographs represent single z-focal plane images from spinning disc confocal microscopy.
- 913 Scale bar =  $20 \mu m$ . (D) Quantification of MCB-GSH fluorescence intensity. E-H: Quantification
- of ROS-specific probes, where HPF detects hydroxyl and perinitrite (E), Si-DMA detects singlet
- 915 oxygen (F), Mitosox detects mitochondrial superoxide (G), and ROS-ID detects cytoplasmic
- 916 superoxide (H). For each ROS probe, fluorescence was normalized against the respective vehicle
- 917 control. For all graphs, data are represented as mean  $\pm$  S.E.M. from three independent
- 918 experiments with 40-50 cells assessed per treatment condition per experiment. One-way
- 919 ANOVA and Tukey's *post-hoc* test were used for (B, E-H), and an unpaired Student's t-test
- 920 performed for (D). \* indicates p<0.05.
- 921 922

Figure 2. ROS agonists prevent lysosome enlargement during acute PIKfyve suppression. *A:* RAW cells pre-labelled with Lucifer yellow and exposed to vehicle or 20 nM apilimod for 40 min. These conditions were then supplemented with additional vehicle or 1 mM H<sub>2</sub>O<sub>2</sub> for 40 min, 1  $\mu$ M rotenone for 60 min, 10  $\mu$ M CDNB for 30 min, 5  $\mu$ M MCB for 30 min or auranofin 10  $\mu$ M for 120 min. Fluorescence micrographs are represented as z-projections of 45-55 z-plane images obtained by spinning disc microscopy. Scale bar: 5  $\mu$ m. *B-D*: Quantification of individual

929 lysosome volume (B), lysosome number per cell (C), and total lysosome volume per cell (D). Data 930 represent mean  $\pm$  S.E.M. from three independent experiments, with 25-30 cells assessed per 931 treatment condition per experiment. One-way ANOVA and Tukey's *post-hoc* test was used, where 932 \* indicates statistical significance between indicated conditions (*p*<0.05).

933

934 Figure 3. ROS scavengers permit lysosome coalescence during acute PIKfyve suppression. 935 A: RAW cells pre-labelled with Lucifer yellow and exposed to vehicle, or 0.5 µM rotenone 60 936 min, or 10 mM N-acetyl-L-cysteine (NAC) 120 min alone, or in presence of 20 nM apilimod for 937 the last 40 min. Fluorescence micrographs are represented as z-projections of 45-55 z-plane images 938 obtained by spinning disc microscopy. Scale bar: 5 µm. B-D: Quantification of individual 939 lysosome volume (B), lysosome number per cell (C), and total lysosome volume per cell (D). Data 940 represent mean + S.E.M. from three independent experiments, with 25-30 cells assessed per 941 treatment condition per experiment. One-way ANOVA and Tukey's post-hoc test was used, where 942 \* indicates statistical significance between indicated conditions (p < 0.05).

943

944 Figure 4: ROS accelerate recovery of lysosome size and number upon PIKfyve reactivation. 945 (A) Top two rows: RAW cells pre-labelled with Lucifer yellow were exposed to either vehicle, 1 946 mM H<sub>2</sub>O<sub>2</sub> 40 min, 1 µM rotenone 60 min, 10 µM CDNB 30 min, or 5 µM MCB 30 min. Bottom 947 two rows: alternatively, RAW cells were first treated with 20 nM apilimod for 60 min (0 h), 948 followed by apilimod removal and replenishment with complete media for 2 h in the presence of 949 vehicle, H<sub>2</sub>O<sub>2</sub>, rotenone, CDNB, or MCB at previously indicated concentrations. Fluorescence 950 micrographs are spinning disc microscopy images with 45-55 z-planes represented as z-951 projections. Scale bar: 5 µm. (B-D) Quantification of individual lysosome volume (B), lysosome

number per cell (C), and total lysosome volume per cell (D). Data are represented as mean  $\pm$  s.e.m. from three independent experiments, with 25-30 cell assessed per treatment condition per experiment. One-way ANOVA and Tukey's *post-hoc* test used for B-D, where \* indicates statistically significant difference between control conditions (*P*<0.05).

956

957

958 Figure 5: Apilimod integrity and PtdIns(3,5)P2 levels are not altered by ROS. (A) RAW cells 959 pre-labelled with Lucifer yellow. Following reactions were performed in complete media in vitro 960 for designated time, prior to adding to cells for an additional 40 min: vehicle; 1 mM H<sub>2</sub>O<sub>2</sub> 40 min; 961 20 nM apilimod 40 min; 20 nM apilimod preincubated with 1 mM H<sub>2</sub>O<sub>2</sub> for 40 min; 20 nM 962 apilimod preincubated with 0.5 mg/L catalase for 60 min; 1 mM H<sub>2</sub>O<sub>2</sub> exposed to 0.5 mg/L catalase 963 for 60 min to neutralize H<sub>2</sub>O<sub>2</sub>, followed by 20 nM apilimod 40 min; or 20 nM apilimod exposed 964 to 1 mM H<sub>2</sub>O<sub>2</sub> for 40 min to test whether H<sub>2</sub>O<sub>2</sub> degraded apilimod, followed by 0.5 mg/L catalase 965 for 60 min to degrade H<sub>2</sub>O<sub>2</sub>. Fluorescence micrographs are spinning disc microscopy images with 966 45-55 z-planes represented as z-projections. Scale bar: 5 µm. (B-D) Quantification of individual 967 lysosome volume (B), lysosome number per cell (C), and total lysosome volume per cell (D). AP 968 (apilimod), CAT (catalase). Data are shown as mean + s.e.m. from three independent experiments, 969 with 25-30 cell assessed per treatment condition per experiment. One-way ANOVA and Tukey's 970 *post-hoc* test used for B-D; \* indicates statistical difference against control condition (P < 0.05). (E-971 F)  ${}^{3}$ H-myo-inositol incorporation followed by HPLC-coupled flow scintillation used to determine 972 PtdIns(3)P and PtdIns(3,5)P2 levels from RAW cells exposed to vehicle alone, or 1 mM H<sub>2</sub>O<sub>2</sub> 40 973 min (E), or 1 µM rotenone 60 min (F), in presence or absence of 20 nM apilimod. Data represent

- 974 + s.d. from three independent experiments. One-way ANOVA and Tukey's *post-hoc* test used for
- 975 E-F; \* indicates statistical difference against control condition (P<0.05).
- 976

977 Figure 6. ROS agents differentially affect the microtubule system. Representative single zfocal plane immunofluorescence micrographs of RAW cells (A) or RPE cells (E) treated with 978 979 vehicle, H<sub>2</sub>O<sub>2</sub>, rotenone, CDNB or MCB at previously used time periods and at the indicated 980 concentrations. After treatment with ROS agents, cells were fixed and immunostained with anti-981  $\alpha$ -tubulin antibodies. Quantification of number of microtubule junctions per cell, number of 982 microtubule branches per cell and average microtubule branch length respectively for RAW cells 983 (B-D) and RPE cells (F-H), and patch area in RPE cells (I). Data are represented as mean + SEM 984 from three independent experiments, with 50-70 cells assessed per treatment per experiment for 985 RAW cells (A-D) and 15-20 cells assessed per treatment per experiment for RPE cells (E-I). One-986 way ANOVA and Tukey's post-hoc test used for B-D and F-I, where \* indicates statistically 987 significant difference between control conditions (P < 0.05). Scale bar: 10 µm (A) or 20 µm (E).

988

989 Figure 7: Distinct ROS agents differentially impact lysosome motility. RAW cells (A-C, 990 Movies 1-6) or RPE cells (D-F, Movies 7-13) were pre-labelled with Lucifer yellow and exposed 991 to either vehicle, 1 mM H<sub>2</sub>O<sub>2</sub> 40 min, 1 µM rotenone 60 min, 10 µM CDNB 30 min, 5 µM MCB 992 30 min, or 5 µM or 10 µM nocodazole for 60 min. Live-cell spinning disc confocal microscopy 993 was performed at a single, mid-cell z-focal plane once every 4 sec for 3 min for RAW cells or 994 every 8 sec for 6 min for RPE cells. Quantification of lysosome speed (A, D), lysosome track 995 length (B, E), and lysosome displacement (C,F) for RAW cells (A-C) or RPE cells (D-F). Data are 996 represented as mean + s.d. from three independent experiments. One-way ANOVA and Tukey's

997 *post-hoc* test used for B-D, where \* indicates *P*<0.05 between indicated conditions and control. 998 Supplemental Movies 1-13 are representative of the live-cell imaging from which shown data was 999 derived from.

1000

1001 Figure 8: H<sub>2</sub>O<sub>2</sub> hinders phagosome-lysosome fusion. (A) RAW cells were treated with H<sub>2</sub>O<sub>2</sub> or 1002 vehicle (H<sub>2</sub>O) for 1h before introducing ZsGreen-expressed E. coli (green). RAW cells were 1003 incubated for 20 minutes in the presence of bacteria and  $H_2O_2$  or vehicle, then RAW cells were 1004 washed with PBS, and further incubated in media containing H<sub>2</sub>O<sub>2</sub> or vehicle for an additional 40 1005 minutes. External bacteria were labeled with rabbit anti-E. coli antibodies (blue) and were 1006 excluded from analysis using a mask. LAMP-1 was labeled with rat anti-LAMP-1 antibodies (red). 1007 (B) Quantification of mean LAMP-1 intensity on bacteria-containing phagosomes. LAMP-1 1008 intensities were quantified from regions that co-localized to internal bacteria (green signal and no 1009 blue signal). Data represented as a scatter plot, where each dot is an individual phagosome from n 1010 = 144 to 179 cells across all independent experiments and conditions. Mean  $\pm$  standard deviation 1011 from three independent experiments is indicated as well. Data analyzed with two-tailed unpaired 1012 t-test (\* indicates p<0.05).

1013

## 1014 Figure 9: H<sub>2</sub>O<sub>2</sub> and rotenone do not induce lysosome damage as detected by galectin-3 puncta.

1015 (A). Macrophages expressing galectin-3-GFP were labelled with Alexa546-conjugated dextran 1016 and then exposed to vehicle, rotenone, or  $H_2O_2$  for ~ 1 h, or with LLOMe for 2 h as a positive 1017 control. Live-cell imaging was done by spinning disc confocal. Scale bar = 10 µm. (B) Mean 1018 number of galectin-3-GFP puncta per cell based on 25-30 cells per condition per experiment from

1019 n=3 independent experiments. One-way ANOVA and Tukey's *post-hoc* test was used, where \* 1020 indicates *P*<0.05 in relation to vehicle condition and ns indicates not significant.

1021

1022 Figure 10: ROS regulate lysosome coalescence independently of Ca<sup>2+</sup>. (A) RAW cells were pre-labelled with Alexa546-conjugated dextran, followed by labelling with the Ca<sup>2+</sup> sensor, Fluo4-1023 1024 AM. Cells were treated with vehicle, or 1 mM H<sub>2</sub>O<sub>2</sub> for 40 min, or 1 µM rotenone for 60 min. 1025 Fluorescence micrographs represent single z-plane images obtained by spinning disc microscopy. 1026 Scale bar: 5 µm. (B) Ratio of Fluo4-AM fluorescence intensities associated with Alexa<sup>546</sup>-1027 conjugated dextran and cytosol. Data are represented as mean + SEM from three independent 1028 experiments, with 20-25 cells assessed per treatment per experiment. Two-way ANOVA and 1029 Tukey's *post-hoc* test were used for (B), where \* indicates P < 0.05 against control conditions. (C) 1030 RAW cells were pre-labelled with Lucifer yellow and exposed to either vehicle,  $1 \text{ mM H}_2O_2$  for 1031 40 min, 1 µM rotenone for 60 min, or 50 µM BAPTA-AM for 70 min, with or without 20 nM 1032 apilimod. Additionally, cells were co-treated with BAPTA-AM and H<sub>2</sub>O<sub>2</sub> or BAPTA-AM and 1033 rotenone, before adding apilimod. Fluorescence micrographs are spinning disc microscopy images 1034 with 45-55 z-planes represented as z-projections. Scale bar: 5 µm. (D-F) Quantification of 1035 individual lysosome volume (D), lysosome number per cell (E), and total lysosome volume per 1036 cell (F). Data is illustrated as mean + SEM from three independent experiments, with 25-30 cell 1037 assessed per condition per experiment. One-way ANOVA and Tukey's post-hoc test used for B-1038 D with \*P < 0.05 compared to indicated control conditions.

1039

1040 Figure 11: Clathrin inhibition does not arrest ROS-mediated lysosome fragmentation during

1041 **PIKfyve reactivation.** (A) RAW cells were pre-labelled with Lucifer yellow and exposed to either

1042 vehicle alone, 1 mM H<sub>2</sub>O<sub>2</sub> for 40 min, 1 µM ikarugamcyin for 1 h, or 20 nM apilimod for 60 min. 1043 For a subgroup of cells treated with apilimod, drug was replaced with fresh media containing either 1044 vehicle, 1 mM  $H_2O_2$ , 1  $\mu$ M ikarugamcyin, or 1 mM  $H_2O_2$  and 1  $\mu$ M ikarugamycin for 2 h. 1045 Fluorescence micrographs are spinning disc microscopy images with 45-55 z-planes represented 1046 as z-projections. Scale bar: 5 µm. (B-D) Quantification of individual lysosome volume (B), 1047 lysosome number per cell (C), and total lysosome volume per cell (D). Data are shown as mean + 1048 s.e.m. from three independent experiments, with 25-30 cell assessed per treatment condition per 1049 experiment. One-way ANOVA and Tukey's *post-hoc* test used for B-D, where \* indicates P < 0.051050 between experimental and control conditions.

1051

1052 Figure 12: ROS promote actin clearance from lysosomes and actin depolymerization abates 1053 lysosomes coalescence during PIKfyve inhibition. (A) RAW cells pre-labelled with Alexa<sup>488</sup>-1054 conjugated dextran followed by treatment with vehicle, 20 nM apilimod for 40 min alone, or in 1055 presence of 10 µM CDNB for 30 min or 1 µM rotenone for 60 min. Cells were fixed with 4% PFA 1056 and stained for actin with phalloidin. Fluorescence micrographs were captured by spinning disc 1057 confocal as single z-planes. The inset is a magnified portion of field of view tracking Alexa<sup>488</sup>-1058 conjugated dextran lysosome(s), phalloidin-stained actin, and as merged channels. Scale bar: 2 1059 µm. (B) Cells were assessed for number of actin puncta structures associated with lysosomes. Data 1060 represent mean + S.E.M. from three independent experiments, with 60-80 cells assessed per 1061 treatment condition across three experiments. One-way ANOVA and Tukey's *post-hoc* test was 1062 used, where \* indicates statistical significance between indicated conditions (p < 0.05). (C) RAW 1063 cells were pre-labelled with Lucifer yellow and exposed to vehicle or 20 nM apilimod for 1 h, 1064 followed by apilimod removal at 0 or 2 h. These conditions were then supplemented with

1065	additional vehicle or 1 $\mu$ M latrunculin A or 5 $\mu$ M cytochalasin B for 1 h. Fluorescence micrographs
1066	are represented as z-projections of 45-55 z-plane images obtained by spinning disc confocal
1067	microscopy. Scale bar: 5 µm. D-F: Quantification of individual lysosome volume (D), lysosome
1068	number per cell (E), and total lysosome volume per cell (F). Data represent mean $\pm$ S.E.M. from
1069	three independent experiments, with 25-30 cells assessed per treatment condition per experiment.
1070	One-way ANOVA and Tukey's post-hoc test was used, where * indicates statistical significance
1071	between indicated conditions ( $p < 0.05$ ).

1072

## **1073 Supplemental Materials**

1074 Supplemental Figure S1: Lower H<sub>2</sub>O<sub>2</sub> concentration prevents apilimod induced lysosome 1075 coalescence. (A) RAW cells were pre-labelled with Lucifer yellow and exposed to either vehicle, 1076 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 40 min in presence or absence of 1 nM or 5 nM apilimod 40 min. Scale bar: 5 1077  $\mu$ m. (B-D) Quantification of individual lysosome volume (B), lysosome number per cell (C), and 1078 total lysosome volume per cell (D). Data are illustrated as mean  $\pm$  SEM from three independent 1079 experiments, with 25-30 cell assessed per condition per experiment. One-way ANOVA and 1080 Tukey's *post-hoc* test was used, where \* indicates *P*<0.05 for the indicated conditions.

1081

Supplemental Figure S2: ROS prevent lysosome enlargement during acute PIKfyve suppression in HeLa and RPE cells. (A) HeLa cells pre-labelled with Lucifer yellow and exposed to vehicle or 100 nM apilimod 40 min, or with 1 mM H<sub>2</sub>O<sub>2</sub> in the presence or absence of 100 nM apilimod for 40 min. Scale bar: 10  $\mu$ m. (B-D) Quantification of individual lysosome volume per lysosome (B), lysosome number per cell (C), and total lysosome volume per cell (D). (E) RPE cells pre-labelled with Lucifer yellow and exposed to vehicle, or 1 mM H<sub>2</sub>O<sub>2</sub>, or 10  $\mu$ M CDNB, in presence or absence of 200 nM apilimod 40 min. Scale bar: 20  $\mu$ m. (F-H) Quantification of individual lysosome volume (F), lysosome number per cell (G), and sum lysosome volume per cell (H). For (B-D) and (F-H), data are represented as mean  $\pm$  SEM. from three independent experiments, with 25-30 cells assessed for (B-D) and 15-20 cells assessed for (F-H) per treatment condition per experiment. One-way ANOVA and Tukey's *post-hoc* test used with \**P*<0.05 compared to indicated control conditions.

1094

1095 Supplemental Figure S3: Quantification and validation of microtubule morphology by image 1096 analysis. Single z-focal plane immunofluorescence micrographs of RAW cells (A) or RPE cells 1097 (E) treated with vehicle, H<sub>2</sub>O<sub>2</sub> or rotenone. After treatment with ROS agents, cells were fixed and immunostained with anti- $\alpha$ -tubulin antibodies. Cells were analyzed for their microtubule 1098 1099 morphology using the ImageJ "skeleton" plugin, converting images into binary "skeleton" 1100 micrographs. Quantification of number of microtubule junctions per cell, number of microtubule 1101 branches per cell and average microtubule branch length for RAW cells (B-D) and RPE cells (F-1102 H). RPE cells were also analyzed for maximum microtubule patch area per cell (I) through ImageJ 1103 using binary filter and watershed segmentation. Data are represented as mean + SD from 5 1104 different fields of view for RAW cells or 10 different fields of view for RPE cell, with 50-70 cells 1105 assessed per treatment condition for RAW cells (A-D) and 15-20 cells assessed per treatment 1106 condition for RPE cells (E-H). One-way ANOVA and Tukey's post-hoc test used for B-D and F-1107 H, where \* indicates statistically significant difference between control conditions (P < 0.05). Scale 1108 bar: 20 µm (A, E).

## 1110 Supplemental Figure S4: Increased microtubule stability does not affect lysosome motility

1111 or lysosome coalescence during PIKfyve inhibition. (A) RAW cells pre-labelled with Lucifer 1112 yellow were exposed to either vehicle, or 1  $\mu$ M or 10  $\mu$ M paclitaxel for 60 min in presence or 1113 absence of 20 nM apilimod for the remaining 40 min. Scale bar: 5 µm. (B-D) Quantification of 1114 individual lysosome volume (B), lysosome number per cell (C), and total lysosome volume per 1115 cell (D). Data are represented as mean + s.e.m. from three independent experiments, with 25-30 1116 cell assessed for (B-D) per treatment condition per experiment. (E-G) RAW cells pre-labelled with 1117 Lucifer yellow were exposed to vehicle or 1  $\mu$ M or 10  $\mu$ M paclitaxel 60 min. Live cell spinning 1118 disc confocal microscopy was performed at single z-focal plane once every 4 sec for 3 min. 1119 Quantification of lysosome speed (E), lysosome displacement (F), and lysosome track length (G) 1120 are shown. Data are represented as mean  $\pm$  s.d. from three independent experiments. One-way 1121 ANOVA and Tukey's *post-hoc* tests were used, where \* indicates P < 0.05 between experimental 1122 and control conditions. Data is based on movies like those represented by Movies 14-16.

1123

1124 Supplemental Figure S5. ROS do not affect Rab7 activation and Arl8b loading onto 1125 lysosomes. RAW cells expressing RILPC33-GFP (A), or Arl8bWT-GFP (B), exposed to vehicle 1126 in absence or presence of 20 nM apilimod 40 min, or 1 mM H<sub>2</sub>O<sub>2</sub> 40 min in presence or absence 1127 of 20 nM apilimod 40 min. Scale bar: 5 µm. (C-D) Quantification of membrane associated 1128 fluorescence intensity of RILPC33-GFP (C) from (A) or Arl8bWT-GFP (D) from (B), normalized 1129 to cytosol fluorescence intensity. Data represent mean + SEM from three independent experiments, 1130 with 15-20 cell assessed per treatment condition per experiment. One-way ANOVA and Tukey's 1131 post-hoc test used for C-D with \*P < 0.05 compared to indicated control conditions. (E) A 1132 representative Western blot of membrane fractions from RAW macrophages treated with vehicle,

rotenone, or H<sub>2</sub>O<sub>2</sub> with or without apilimod. Blots were probed with antibodies against Rab7,
Arl8a/b, and LAMP1, the latter used to benchmark membrane levels. (F) Relative levels of
Arl8ab/b or Rab7 as a ratio to LAMP1 band intensity. Data are shown as mean + standard deviation
from n=3 independent experiments.

1137


1138 Supplemental Figure S6. H<sub>2</sub>O<sub>2</sub> boosts recruitment of clathrin and dynamin to membranes. (A) RPE cells stably expressing clathrin heavy chain-eGFP were pre-labelled with Alexa<sup>546-</sup> 1139 1140 conjugated dextran and treated with vehicle, 1 mM H<sub>2</sub>O<sub>2</sub>, or 200 nM apilimod with or without 1 1141 mM H<sub>2</sub>O<sub>2</sub>. Single z- plane images were acquired every 2 min for 40 min across all treatments. Fluorescence micrographs represent single z-plane images at 0 min and 40 min for each treatment 1142 obtained by spinning disc microscopy. The inset is a magnified portion of field of view tracking 1143 1144 Alexa<sup>546</sup>-conjugated dextran lysosome(s) or clathrin-eGFP separate or merged. Scale bar: 7 µm. B. Ratio of clathrin-eGFP fluorescence intensities associated with Alexa<sup>546</sup>-conjugated dextran 1145 1146 and cytosol time points: 0, 10, 20, 30, and 40 min. Data are represented as mean + s.e.m. from five 1147 to six independent experiments, with 1-3 cells assessed per treatment condition per experiment. 1148 Two-way ANOVA and Tukey's *post-hoc* test were used for (B), where \* indicates P < 0.05 against 1149 control conditions. (C) RAW cells were treated with vehicle or 1 mM H<sub>2</sub>O<sub>2</sub> for 40 min, lysed and homogenates fractionated through a sucrose gradient ultracentrifugation. Fractions were 1150 1151 immunoblotted against LAMP1 and VAPB to respectively identify lysosome and ER fractions, 1152 and aganst clathrin heavy chain and dynamin 2. Protein expression for clathrin heavy chain (D) or 1153 dynamin 2 (E) were normalized to LAMP1 for fractions 3 to 6. Data are represented as mean + 1154 s.d. from three independent experiments. Unpaired Student's t-test was used for (D-E), where \* 1155 indicates *P*<0.05 against vehicle control conditions.


1157	Supplemental Figure S7. Dynamin inhibition does not affect lysosome fragmentation during
1158	during PIKfyve reactivation. (A) RAW cells were pre-labelled with Lucifer yellow and exposed
1159	to either vehicle, 30 $\mu$ M dyngo-4A for 2 h, 1 mM H <sub>2</sub> O <sub>2</sub> for 40 min, or 1 $\mu$ M rotenone for 1 h, or
1160	20 nM apilimod for 60 min. Additional subgroup of apilimod treated cells were then washed and
1161	incubated with apilimod-free media and changed for 2 h in the presence of vehicle, dyngo-4A,
1162	H2O2, and dyngo4-A plus H2O2 for a total time of 2 h without apilimod. Fluorescence
1163	micrographs are spinning disc microscopy images with 45-55 z-planes represented as z-
1164	projections. Scale bar: 5 µm. (B-D) Quantification of individual lysosome volume (B), lysosome
1165	number per cell (C), and total lysosome volume per cell (D). Data is illustrated as mean $\pm$ s.e.m.
1166	from three independent experiments, with 25-30 cell assessed per treatment condition per
1167	experiment. One-way ANOVA and Tukey's <i>post-hoc</i> test used for B-D with *P<0.05 compared
1168	to indicated control conditions.
1169	
1170	
1171	
1172	
1173	
1174	
1175	Supplemental Movie 1: Lysosome motility for vehicle-treated RAW macrophages. Live-cell
1176	imaging of RAW macrophages pre-labelled with Lucifer yellow and treated with vehicle-only.
1177	Single-plane acquired every 4 sec for 3 min. Time and scale are as indicated.
1178	

1179	Supplemental Movie 2: Lysosome motility for H2O2-treated RAW macrophages. Live-cell
1180	imaging of RAW macrophages pre-labelled with Lucifer yellow and treated with 1 mM $\mathrm{H_2O_2}$ for
1181	40 min. Single-plane acquired every 4 sec for 3 min. Time and scale are as indicated.
1182	
1183	Supplemental Movie 3: Lysosome motility for rotenone-treated RAW macrophages. Live-
1184	cell imaging of RAW macrophages pre-labelled with Lucifer yellow and treated with 1 $\mu M$
1185	rotenone for 60 min. Single-plane acquired every 4 sec for 3 min. Time and scale are as indicated.
1186	
1187	Supplemental Movie 4: Lysosome motility for CDNB-treated RAW macrophages. Live-cell
1188	imaging of RAW macrophages pre-labelled with Lucifer yellow and treated with 10 $\mu M$ CDNB
1189	30 min. Single-plane acquired every 4 sec for 3 min. Time and scale are as indicated.
1190	
1191	Supplemental Movie 5: Lysosome motility for MCB-treated RAW macrophages. Live-cell
1192	imaging of RAW macrophages pre-labelled with Lucifer yellow and treated with 5 $\mu$ M MCB 30
1193	min. Single-plane acquired every 4 sec for 3 min. Time and scale are as indicated.
1194	
1195	Supplemental Movie 6: Lysosome motility for nocodazole-treated RAW macrophages. Live-
1196	cell imaging of RAW macrophages pre-labelled with Lucifer yellow and treated with 10 $\mu M$
1197	nocodazole 60 min. Single-plane acquired every 4 sec for 3 min. Time and scale are as indicated.
1198	
1199	Supplemental Movie 7: Lysosome motility for vehicle-treated RPE cells. Live-cell imaging of
1200	RPE cells pre-labelled with Lucifer yellow and treated with vehicle-only. Single-plane acquired
1201	every 8 sec for 6 min. Time and scale are as indicated.

1203	Supplemental Movie 8: Lysosome motility for H <sub>2</sub> O <sub>2</sub> -treated RPE cells. Live-cell imaging of
1204	RPE cells pre-labelled with Lucifer yellow and treated with 1 mM H <sub>2</sub> O <sub>2</sub> 40 min. Single-plane
1205	acquired every 8 sec for 6 min. Time and scale are as indicated.
1206	
1207	Supplemental Movie 9: Lysosome motility for rotenone-treated RPE cells. Live-cell imaging
1208	of RPE cells pre-labelled with Lucifer yellow and treated with 1 $\mu$ M rotenone 60 min. Single-
1209	plane acquired every 8 sec for 6 min. Time and scale are as indicated.
1210	
1211	Supplemental Movie 10: Lysosome motility for CDNB-treated RPE cells. Live-cell imaging
1212	of RPE cells pre-labelled with Lucifer yellow and treated with 10 µM CDNB 30 min. Single-plane
1213	acquired every 8 sec for 6 min. Time and scale are as indicated.
1214	
1215	Supplemental Movie 11: Lysosome motility for MCB-treated RPE cells. Live-cell imaging of
1216	RPE cells pre-labelled with Lucifer yellow and treated with 5 µM MCB 30 min. Single-plane
1217	acquired every 8 sec for 6 min. Time and scale are as indicated.
1218	
1219	Supplemental Movie 12: Lysosome motility for nocodazole five micromolar treated RPE
1220	cells. Live-cell imaging of RPE cells pre-labelled with Lucifer yellow and treated with 5 $\mu$ M
1221	nocodazole 60 min. Single-plane acquired every 8 sec for 6 min. Time and scale are as indicated.
1222	

1223	Supplemental Movie 13: Lysosome motility for nocodazole ten micromolar treated RPE
1224	cells. Live-cell imaging of RPE cells pre-labelled with Lucifer yellow and treated with 10 $\mu$ M
1225	nocodazole 60 min. Single-plane acquired every 8 sec for 6 min. Time and scale are as indicated.
1226	
1227	Supplemental Movie 14: Lysosome motility for vehicle-treated RAW macrophages. Live-cell
1228	imaging of RAW cells pre-labelled with Lucifer yellow and treated with vehicle-only. Single-
1229	plane acquired every 4 sec for 3 min. Time and scale are as indicated.
1230	
1231	Supplemental Movie 15: Lysosome motility for paclitaxel one micromolar treated RAW
1232	macrophages. Live-cell imaging of RAW cells pre-labelled with Lucifer yellow and treated with
1233	1 µM paclitaxel 60 min. Single-plane acquired every 4 sec for 3 min. Time and scale are as
1234	indicated.
1235	
1236	Supplemental Movie 16: Lysosome motility for paclitaxel ten micromolar treated RAW
1237	macrophages. Live-cell imaging of RAW cells pre-labelled with Lucifer yellow and treated with
1238	10 µM paclitaxel 60 min. Single-plane acquired every 4 sec for 3 min. Time and scale are as
1239	indicated.
1240	





0

-+ - -+

+ -

\_ +

+

Apilimod

+


-

Rotenone NAC

+

+ +

Apilimod



50

٢

+ --+ -+

Rotenone -NAC -

r

-

+ .

+

-

-+ +

Apilimod

Rotenone NAC

